CONFIDENTIA L
The GlaxoSmithKline group of companies 200182
1Division :World wide Development
Information Type :Reporting and Analysis Plan (RAP)
Title :Reporting and Analysis Plan for a randomized double- blind 
(sponsor unblind), placebo -controlled, multi- centred phase IIa study 
to evaluate the safety and eff icacy of 13 weeks of once daily oral 
dosing of the selective androgen receptor modulator (SARM) 
GSK2881078 in older men and post menopausal women with 
COPD and muscle weakness, participating in home exercise
Compound Number :GSK 28810 78
Effective Date :09-JAN-2020
Description:
The purpose of this RAP is to describe the planned analyses and output to be included in 
the Clinical Study Report for Protocol 200182 Amendment 3.
This RAP is intended to describe the safety andefficacy analyses required for the study. 
This RAP will be provided to the study team members to convey the content of the 
Statistical Analysis Complete (SAC) deliverables
RAP Author(s):
Author
Associate Statistician (Respiratory, Biostatistics)
Co-Author
Principle Biostatistician, (Parexel)
Copyright 2 020the GlaxoSmithKline group of companies. All rights reserved.  Unauthorised 
copying or use of this information is prohibited.
PPD
PPD
CONFIDENTIA L
The GlaxoSmithKline group of companies 200182
2RAP Team Reviewers (Method: E- mail)
Approver Date
Clinical Investigation Lead ( Discovery Medicine , CPEM )07-JAN-2020
 
Medical Monitor, Discovery Medicine Lead, Discovery Medicine, 
CPEM07-JAN-2020
06-JAN-2020 Data Quality Lead (Clinical Data Sciences Canada , RD Projects 
Clinical Platf orms & Sciences)
06-JAN-2020Clinical Program Lead (GCSD)
 06-JAN-2020Safety Scientist , Safety and Medical Governance Scientist
Medical Director ,Safety and Medical Governance : 06-JAN-2020
06-JAN-2020Regulatory Affairs (Global Regulatory Affairs)
06-JAN-2020 Clinical Pharmacologist (Clinical Pharmacology Modelling and 
Simulations)
08-JAN-2020Patient Centred Outcomes Lead (Value Evidence and Outcom es)
Study Programmer (FPD, Clinical programming) 08-JAN-2020
Clinical Statistics and Clinical Programming Line Approv als:
(Method: Pharma TMF e -signature)
Approver Date
09-JAN-2020Statistics Director (FPD, Clinical Statistics)
09-JAN-2020Programming manager (FPD, Clinical Programming)
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CONFIDENTIA L
200182
3TABLE OF CONTENTS
PAGE
1.INTRODUCTION ................................ ................................ ................................ ......6
2.SUMMARY OF KEY PROTOCOL INFORM ATION ................................ .................. 6
2.1. Changes to the Protocol Defined Statistical Analysis Plan ............................ 6
2.2. Study Objectives and Endpoints ................................ ................................ ...9
2.3. Study Design ................................ ................................ .............................. 11
2.4. Statistical Analyses ................................ ................................ ..................... 12
3.PLANNED ANALYSES ................................ ................................ .......................... 13
3.1. Final Analyses ................................ ................................ ............................ 13
4.ANALYSIS POPULATIONS ................................ ................................ ................... 13
4.1. Protocol Deviations ................................ ................................ ..................... 14
5.CONSIDERATIONS FOR D ATA ANALYSES AND DAT A HANDLING 
CONVENTIONS ................................ ................................ ................................ .....15
5.1. Study Treatment & Sub -group Display Descriptors ................................ .....15
5.2. Baseline Definitions ................................ ................................ .................... 15
5.3. Multicentre Studies ................................ ................................ ..................... 17
5.4. Examination of Covariates, Other Strata and Subgroups ............................ 17
5.4.1. Covariates and Other Strata ................................ ........................ 17
5.4.2. Examination of Sub groups ................................ ........................... 17
5.5. Multiple Comparisons and Multiplicity ................................ ......................... 17
5.6. Other Considerations for Data Analyses and Data Handling 
Conventions ................................ ................................ ................................ 17
6.STUDY POPULATION ANA LYSES ................................ ................................ .......18
6.1. Overview of Planned Study Population Analyses ................................ ........ 18
7.EFFICACY ANALYSES ................................ ................................ .......................... 20
7.1. Primary Efficacy Analyses ................................ ................................ .......... 20
7.1.1. Summary Measure ................................ ................................ ......20
7.1.2. Endpoint / Variables ................................ ................................ .....20
7.1.3. Population of Interest ................................ ................................ ...20
7.1.4. Statistical Analyses / Methods ................................ ..................... 20
7.1.4.1. Statistical Methodology Specific ation .......................... 20
7.2. Secondary Efficacy Analyses ................................ ................................ ......22
7.2.1. Endpoint / Variables ................................ ................................ .....22
7.2.2. Summary Measure ................................ ................................ ......23
7.2.3. Population of Interest ................................ ................................ ...24
7.2.4. Statistical Analyses / Methods ................................ ..................... 24
7.2.4.1. Statistical Methodology Specification .......................... 24
7.3. Exploratory Efficacy Analyses ................................ ................................ .....28
7.3.1. Endpoint / Variables ................................ ................................ .....28
7.3.2. Summary Measure ................................ ................................ ......28
7.3.3. Population of Interest ................................ ................................ ...28
7.3.4. Statistical Analyses / Methods ................................ ..................... 28
7.3.4.1. Statistical Meth odology Specification .......................... 28
CONFIDENTIA L
200182
47.3.4.2. Other Analyses ................................ ........................... 29
8.SAFETY ANALYSES ................................ ................................ ............................. 30
8.1. Adverse Events Analyses ................................ ................................ ........... 30
8.2. Adverse Events of Special Int erest Analyses ................................ .............. 30
8.3. Clinical Laboratory Analyses ................................ ................................ .......30
8.4. Other Safety Analyses ................................ ................................ ................ 31
9.PHARMACOKINETIC ANAL YSES ................................ ................................ ......... 32
10.POPULATION PHARMACOK INETIC (POPPK) ANALY SES................................ ..32
11.REFERENCES ................................ ................................ ................................ .......33
12.APPENDICES ................................ ................................ ................................ ........ 34
12.1. Appendix 1: Protocol Deviation Management and Definitions for Per 
Protocol Population ................................ ................................ ..................... 34
12.1.1. Exclusions from Per Protocol Population ................................ .....34
12.2. Appendix 2: Schedule of Activities ................................ .............................. 35
12.2.1. Protocol Defined Schedule of Events ................................ ........... 35
12.3. Appendix 3: Assessment W indows ................................ ............................. 40
12.3.1. Definitions of Assessment Windows for Analyses ........................ 40
12.4. Appendix 4: Study Phases ................................ ................................ .......... 41
12.4.1. Study Phases ................................ ................................ .............. 41
12.4.2. Study Phases for Concomitant Medication ................................ ...41
12.5. Appendix 5: Data Display Standards & Handling Conventions .................... 42
12.5.1. Reporting Process ................................ ................................ .......42
12.5.2. Reporti ng Standards ................................ ................................ ....42
12.6. Appendix 6: Derived and Transformed Data ................................ ............... 44
12.6.1. General ................................ ................................ ........................ 44
12.6.2. Efficacy ................................ ................................ ........................ 44
12.6.3. Safety ................................ ................................ .......................... 47
12.7. Appendix 7: Reporting Standards for Missing Data ................................ .....52
12.7.1. Premature W ithdrawals ................................ ................................ 52
12.7.2. Handling of Missing Data ................................ ............................. 52
12.7.2.1. Handling of Missing and Partial Dates ........................ 52
12.8. Appendix 8: Values of Potential Clinical Importance ................................ ...53
12.8.1. Laboratory Values ................................ ................................ ........ 53
12.8.2. ECG ................................ ................................ ............................. 54
12.8.3. Vital Signs ................................ ................................ .................... 54
12.9. Appendix 9: Model Checking and Diagnostics for Statistical 
Analyses ................................ ................................ ................................ .....55
12.10. Appendix 10: Abbreviations & Trade Marks ................................ ................ 56
12.10.1. Abbreviations ................................ ................................ ............... 56
12.10.2. Trademarks ................................ ................................ ................. 58
12.11. Appendix 11: List of Data Displays ................................ .............................. 59
12.11.1. Data Display Numbering ................................ .............................. 59
12.11.2. Mock Example Shell Referencing ................................ ................ 59
12.11.3. Deliverables ................................ ................................ ................. 59
12.11.4. Study Population Tables ................................ .............................. 60
12.11.5. Efficacy Tables ................................ ................................ ............ 62
12.11.6. Efficacy Figures ................................ ................................ ........... 69
CONFIDENTIA L
200182
512.11.7. Safety Tables ................................ ................................ ............... 70
12.11.8. Safety Figures ................................ ................................ ............. 75
12.11.9. Pharmacokinetics Tables ................................ ............................. 75
12.11.10. ICH Listings ................................ ................................ ................. 76
12.11.11. Non-ICH Listings ................................ ................................ .......... 80
12.12. Appendix 12: Example Mock Shells for Data Displays ................................ 86
CONFIDENTIA L
200182
61. INTRODUCTION
The purpose of this reporting and analysis plan (RAP) is to describe the analyses to be included in 
the Cli nical Study Report for Protocol.
2. SUMM ARY OF KEY PROTOCOL I NFORM ATION
2.1. Changes to the Protocol Defined Statistical A nalysis Plan
Changes from the originally planned statistical analysis specified in the protocol are outlined in 
Table 1.
Table 1 Changes to Protocol Defined A nalysis Plan
Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statistical Analysis Plan Rationale for Changes
An interim analysis for the 
assessment of futility is 
planned (Sectio n 5.1 in the 
protocol) . Remove d all references 
to the interim analysis Decidedtocancel the 
planned interim analysis ,
as per the Note to File 
dated 5March2019
A multivariate Bayesian 
approach using non -
informative priors will be 
employed, data permitti ng, to 
further explore the 
relationships between changes 
in strength and lean mass and 
the functional outcomes (ISWT, 
ESWT,) and to inform decision 
making . (Section 10.3.3 in the 
protocol)Multivariate Bayesian 
approach will not be 
planned Decision making
endpoints will be 
analysed using a 
univariate Bayesian 
approach and a decision -
making framework 
prospectively defined for 
these endpoints. Any 
multivariate Bayesian 
analyses will be 
considered as post -hoc 
analysis if data 
warranted. 
NA Analysis of % cha nge 
from baseline in 
appendicular, and total 
lean mass as assessed 
by Dual -energy X -ray 
Absorptiometry (DXA) 
will be plannedTo assist clinical team 
review of the secondary 
endpoints
NA Analysis of % change 
from baseline in 
Constant Work Rate 
(CWR) durati on from 
endurance shuttle 
walking test and peak 
performance from 
incremental shuttle To assist clinical team 
review of the secondary 
endpoints
CONFIDENTIA L
200182
7Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statistical Analysis Plan Rationale for Changes
walking test will be 
planned
NA The responder definition 
and analysis between 
treatment group s
(GSK2881078 / Plac ebo) 
for COPD Assessment 
Test (CAT) and St 
George Respiratory 
Questionnaire -COPD 
(SGRQ -c) will be addedTo assist clinical team 
review of the secondary 
endpoints
NA A Bayesian analysis 
added for the endpoint 
‘times for chair rise ’To assist clinical team 
review of the secondary 
endpoints
Log-transformed leg press 
strength data will be conducted 
as supportive analysis of the 
primary endpointLog-transformed leg 
press strength data will 
be analysed only when 
the model assumptions 
are not met, and log -
transf ormation is 
applicableData will only be 
analysed by appropriate 
methods, therefore 
transformations of the 
data prior to analysis will 
only be done if 
applicable.
Log-transformed supportive 
analysis for all the endpoints in 
case of violation of 
assumptio ns Log-transformed data 
will be analysed only 
when the model 
assumptions are not 
met, and log -
transformation is 
applicableData will only be 
analysed by appropriate 
methods, therefore 
transformations of the 
data prior to analysis will 
only be done if 
applicable.
Exploratory endpoint: Further 
exploratory analyses may 
include changes from baseline 
in size of inspiratory muscles 
and/ or other organs . Will not analysed in this 
RAPThere is no data 
collected
Exploratory endpoint: Gain 
further insights into the 
participants’ experience with 
study treatment and their 
participation in the trial.Will not analysed in this 
RAPExit interview data will be 
reported separately
The ‘Analysis Population’ (AP) 
is defined as participants in the 
‘All Participants’ popu lation 
having baseline and at least 
one post -baseline assessment 
of the strength, lean mass or 
functional endpoint (Section The ‘Analysis 
Population’ (AP) is 
defined as participants 
in the ‘All Participants’ 
population having 
baselin e and at least 
one post -baseline The endpoint PROactive 
scores also added to the 
definition.
CONFIDENTIA L
200182
8Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statistical Analysis Plan Rationale for Changes
10.2 in the protocol ). assessment of the lean 
mass or PROactive 
scores or any of the 
functional endpoints.
The ‘Per Protocol Population’ 
will consist of any AP 
participants who are com pliant 
with protocol -specific criteria 
and who do not experience an 
exacerbation during the 
treatment phase of the study. 
Participants with specified 
protocol deviations and those 
failing to complete the Week 13 
functional assessments will be 
excluded (Section 10.2 in the 
protocol ).The ‘Per Protocol 
Population’ will consist 
of any AP participants 
who are compliant with 
protocol -specific criteria 
and who do not 
experience an 
exacerbation during the 
treatment phase of the 
study. Participants with 
specified p rotocol 
deviations and those 
failing to complete the 
Week 13 functional 
assessments or 
PROactive scores or 
lean mass will be
excluded .The endpoint PROactive 
scores also added to the 
definition.
CONFIDENTIA L
200182
92.2. Stud y Objectives and Endpoints
Objectives Endpoints
Primar y Objectives Primary Endpoints
Assess the safety and tolerability 
of approximately 13 weeks of 
dosing of GSK2881078.Safety and tolerability of GSK2881078 as assessed 
by clinical monitoring of blood pressure, heart rate, 
electrocardiogram (ECG) and labora tory safety data, 
as well as reporting of adverse events (AEs)
 Assess the effect of approximately 
13 weeks of dosing of 
GSK2881078 on leg strength in 
older men and postmenopausal 
women with COPD and muscle 
weakness, participating in home 
exercise.% chang e from baseline and change from baseline in 
maximum leg press strength following 1 repetition 
maximum (1 -RM)
Secondary Objectives Secondary Endpoints
Assess the effect of approximately 
13 weeks of dosing of 
GSK2881078 on lean soft tissue 
mass.Change fr om baseline in appendicular, and total lean 
mass as assessed by Dual -energy X -ray 
Absorptiometry (DXA) .
 Assess the effect of approximately 
13 weeks of dosing of 
GSK2881078 on exercise 
capacity. Change from baseline in total Short Physical 
Performance Batt ery (SPPB) score and times for 
chair rise and 4 m gait speed.
Change from baseline in Constant Work Rate 
(CWR) duration from endurance shuttle walking 
test. 
Change from baseline in peak performance from 
incremental shuttle walking test.
 Assess the effect of approximately 
13 weeks of dosing of 
GSK2881078 on patient reported 
outcomes, levels of physical 
activity, activities of daily living 
and the patient perspective of 
efficacy. Change from baseline in COPD Assessment Test 
(CAT). 
Change in PROactive endpo ints (individual 
components and total score).
Change in physical activity measures as assessed 
via an accelerometer.
Patient Global Impression of Change.
Patient Global Rating of Severity.
Change in St George Respiratory Questionnaire -
COPD (SGRQ -c) total s core and domains
 Assess the effect of approximately 
13 weeks of dosing of 
GSK2881078 on respiratory 
function . Change from baseline in forced expiratory volume in 
1 second (FEV1)
Change from baseline in Sniff nasal inspiratory 
pressure (SnIP) .
CONFIDENTIA L
200182
10Objectives Endpoints
 Characteris e the population 
pharmacokinetic (PK) profile of 
approximately 13 weeks of dosing 
of GSK2881078 in older men and 
post-menopausal women with 
COPD and muscle weakness . Model specific PK parameters of GSK2881078 
(e.g., oral clearance, oral steady -state volume of 
distribution).
Exploratory Objectives Endpoints                                  
 Assess the safety of 13 weeks of 
dosing of GSK2881078 in older 
men and postmenopausal women 
in a subset of up to 15 male and 
15 female participants with COPD 
via magnet ic resonance imaging 
(MRI). Changes from baseline in hepatic, prostate (males) 
and cardiac structure and function as assessed via 
MRI. Further exploratory analyses may include 
changes from baseline in size of inspiratory muscles 
and/ or other organs.
 Cond uct semi -structured exit 
interviews . Gain further insights into the participants’ 
experience with study treatment and their 
participation in the trial.
 Assess the effect of 13 weeks of 
dosing of GSK2881078 in older 
men and postmenopausal women 
on peripher al strength . Changes from baseline in handgrip strength .
Potentially explore adherence to exercise program 
(daily physical activity and thrice -weekly 
strengthening exercises) .
CONFIDENTIA L
200182
112.3. Stud y Design
Overview of Study Design and Key Features
Design
FeaturesThis study is a randomized, placebo -controlled, double -blind (sponsor unblind), 
parallel group, multi -centre phase IIa trial in two equal sized cohorts (male or 
female). Following completion of screen assessments, baseline assessments 
will be conducted in elig ible participants and, in each cohort, the participants 
will be randomized 1:1 to GSK2881078 or matching placebo.
This study will assess the effect of GSK2881078 on physical strength and 
function after 13 weeks of treatment. The placebo group will serve as an 
appropriate control group tolimit evaluation bias in the study endpoints. No 
suitable active comparator is currently available. Both treatment and control 
groups will be asked to participate in a standardized home exercise program.
Dosing Study treat ment will consist of two dosing cohorts (Male: placebo or 2.0 mg of 
GSK2881078; Postmenopausal female: placebo or 1.0 mg of GSK2881078).
Dosing levels: 1.0 mg for women (2 x 0.5mg capsules) once daily
2.0 mg for men (2x 1.0mg capsules) once daily
Placebo: 2 capsules once daily
Time & 
EventsRefer to Appendix 2 : Schedule of Activities
Treatment 
AssignmentMale and post -menopausal female participants who are between 50 and 75 
years of age and meet all other study ent ry criteria will be assigned to one of 
the treatments (Male: placebo or 2.0 mg of GSK2881078; Postmenopausal 
female: placebo or 1.0 mg of GSK2881078) in a ratio of 1:1 in accordance with 
the randomization schedule.
CONFIDENTIA L
200182
12Overview of Study Design and Key Features
Interim 
AnalysisNo interim analysis is planned for the study (See Note to File dated 
5March2019 )
2.4. Statistical Analyses
Change from baseline and percent change from baseline in maximum leg press strength following 
1-RM will be analyzed separately using mixed models repeated measures (MMRM) mod els with 
effects for treatment, day, treatment x day, and baseline strength. Differences in least squares 
means between the GSK2881078 treated group and placebo treated group will be calculated (i.e.; 
GSK2881078 -placebo) along with associated 90% CIs. The analysis will be done separately for 
each gender.
The analyses will be performed using all available data from participants in both the analysis 
population and the Per Protocol Population. The effects of potential predictors of response 
including baselin e BMI and percent predicted FEV1 willbe explored.
Additionally, a Bayesian approach using a non -informative prior will be conducted to estimate the 
posterior distribution and to estimate the probability that the true treatment difference of % change 
from baseline strength at week 13 (Day 90)is ≥ 9% .Additional threshold values and timepoints will 
also be presented for all decision -making endpoints including other key secondary endpoints.
Model and distributional assumptions underlying each analysis will be assessed and the details 
can be fou nd at Appendix 9 . 
Safety data will be presented in tabular and/or graphical format and summarized descriptively 
according to GSK’s Integrated Data Standards Library (IDSL) standards. No formal statistical 
comparisons will be made for the safety data.
Sample size estimations and explorations into sample size sensitivity are given in Section 10.1 of 
the protocol.
CONFIDENTIA L
200182
133. PLANNED ANALYSES
3.1. Final A nalyses
The final planned primary analyses will be performed after the completion of the following 
sequential steps:
1. All participants have completed the study as defined in the protocol 
2. All required database cleaning activities have been completed and final database release
(DBR) and database freeze (DBF) has been declared by Data Manage ment .
3. All criteria for unblinding the randomi zation codes have been met. 
4. Randomiz ation codes have been distributed accor ding to RandAll NG procedures.
4. ANALYSIS P OPUL ATIONS
Population Definition / Criteria Analyses Evaluated
Screened All participants who were screened for eligibility 
and allocated a subject number.Screened subjects
Enrolled All participants who passed screening and entered the 
study.
Note screening failures (who never passed screening 
even if rescreened) and participants screened but 
never enrolled into the study (Reserve, Not Used) are 
excluded from the Enrolled population as they did not 
enter the study.Study Population 
All Participants The ‘All Participants Population’ is defined as all 
randomized participants who receive at least one dose 
of study medication.
This population will be based on the treatment the 
participant was randomized to.Study Population
Safety The ‘Safety Population’ is defined as all randomized 
participants who receive at least one dose of study 
medication.
This population will be based on the treatment the 
participant received .Safety
Analysis (AP) The ‘Analysis Population’ (AP) is defined as 
participants in the ‘All Participants’ population having 
baseline and at least one post -baseline assessment of 
thelean mass or PROactive scores or any of the 
functional endpoint s.
This population will be based on the treatment the 
participant was randomized to. The functional 
endpoints include leg press strength, peak 
performance from Incremental shuttle walking test,
Constant Work Rate (CWR) duration from
endurance shuttle walk ing test , total SPPB score 
and handgrip strength .Efficacy
CONFIDENTIA L
200182
14Population Definition / Criteria Analyses Evaluated
Per Protocol The ‘Per Protocol Population’ will consist of any AP 
participants who are compliant with protocol -specific 
criteria and w ho do not experience an exacerbation 
during the treatment phase of the study. Participants 
with specified protocol deviations and those failing to 
complete any of the Week 13 functional assessments
or PROactive scores or lean mass will be excluded. 
This po pulation will be based on the treatment the 
participant was randomized to .  Further details will be 
given in Section 12.1.1 .Efficacy (Strength, 
SGRQ, PROactive 
Constant Work 
Rate (CWR) 
duration from 
endurance shutt le 
walking test and 
time for repeated 
chair rise )
Pharmacokinetic
(PK)The ‘PK Population’ is defined as participants in the 
‘All Participants’ population for whom a PK sample was 
obtained and analysed for GSK2881078.PK
1.Refer to Appendix 11 : List of Data Displays which details the population used f or each display .
4.1. Protocol Deviations
Important protocol deviations (including deviations related to study inclusion/exclusion criteria, 
conduct of the trial, patient mana gement or patient assessment) will be summari sed and listed .
Important deviations which result in exclusion from the analysis population will also be summarised
and listed. (Please refer to Appendix 1 : Protocol Devi ation Management and Definitions for Per 
Protocol Population ).
Protocol deviations will be tracked by the study team throughout the conduct of the study in 
accordance with the ‘Proto col Deviation Specification version 6.0 dated 28 Nov 2019
oData will be rev iewed prior to unblinding and freezing the database to ensure all important 
deviations and deviations which may lead to exclusion from the analysis are captured and 
categori sed on the protocol deviations dataset. It will not be possible to identify whether
subjects received a different treatment to the one they were randomised to until post 
unblinding, hence this protocol deviation will be identified after unblinding the database.
oA blinded data review meetings (BDRM) will be handled before the final databa se release 
(DBR)
oThis dataset will be the basis for the summaries and listings of protocol deviations.
A listing of all inclusion/exclusion criteria deviations will also be provided. This listing will be based 
on data as recorded on the inclusion/exclusion page of the eCRF.
CONFIDENTIA L
200182
155. CONSIDERA TIONS FOR DATA ANALYSES ANDDATA
HANDLING CONVENTIONS
5.1. Stud y Treatment & Sub -group Display  Descriptors
The analysis and summary will be separately analysed by gender . All graphical displays will 
present results for males and fema les on separate pages. Sex will be either a subtitle or 
subheading (“by” variable) on these displays.
For each efficacy analysis table, the results for female will displayed first and then repeat edfor 
male; for other tables, the summary will be presented in the order of female and male. Listings will 
be sorted by gender.
Treatment Group Descriptions
Treatment Group Data Displays for Reporting 
Code Description Description Order in TLF 
A PTM GSK2881078 1.0mg Placebo 1 -Female
B GSK2881078 1.0 mg GSK 2881078 1.0 mg 2-Female
C PTM GSK2881078 2.0mg Placebo 1 -Male
D GSK2881078 2.0 mg GSK 2881078 2.0 mg 2-Male
Treatment comparisons will be displayed as follows using the descriptors as specified and 
separated by gender :
Female: GSK 2881078 1.0mg vs Placebo
Male: GSK2881078 2.0 mg vs Placebo
5.2. Baseline Definition s
Parameter Study Assessments Considered as 
BaselineBaseline Used in 
Data Display
Screening Day -9 Day 1 (Pre -Dose)
Efficacy
Leg Strength X X whichever is latest *
Incremental Shuttle Walk T est X X whichever is higher
Endurance Shuttle Walk Test X Day 1
Dual-energy X -ray Absorptiometry
(DXA)X Day 1
Short Physical Performance 
Battery (SPPB)X X whichever is latest*
COPD Assessment Test (CAT) X Day 1
Patient Global Rating of Seve rity 
(PGRS)X Day 1
St George Respiratory X Day 1
CONFIDENTIA L
200182
16Parameter Study Assessments Considered as 
BaselineBaseline Used in 
Data Display
Screening Day -9 Day 1 (Pre -Dose)
Questionnaire COPD (SGRQ -c)
PROactive Physical Activity X X See detail below **
Spirometry X X whichever is latest*
Sniff Nasal Inspiratory Pressure 
(SnIP)X X whichever is latest*
Safety
Vital Signs X X whichever is latest*
12-lead ECG X X whichever is latest*
Haematology X X whichever is latest*
Clinical Chemistry X X whichever is latest*
Urinalysis X X whichever is latest*
hsCRP, Fibrinogen X Day 1
Lipid panel X X whichever is l atest*
PSA X X whichever is latest*
HbA1c X screening
Exploratory
Cardiac and liver MRI X Day 1
Handgrip strength X X whichever is latest*
Reproductive Tissue Biomarkers X Day 1
Bone Biomarkers X Day 1
***Exploratory Biomarkers X Day 1
***Monitored home exercise 
programX X whichever is latest*
*Baseline value will be the latest pre -dose assessment with a non -missing value, including those 
from unscheduled visits. If time is not collected, Day 1 assessments are assumed to be taken pr ior 
to first dose and used as baseline.
**Baseline will be the average of the data collected from the 7-day period after Day -9device 
dispense .
***Exploratory Biomarkers and home exercise program will be analysed separately and will not be 
reported as par t of this study Statistical Analysis Complete reporting .
Unless otherwise stated, if baseline data is missing no derivation will be performed and baseline 
will be set to missing .
CONFIDENTIA L
200182
175.3. Multicentre Studies
In this multicentre global study, enrolment will be prese nted by i nvestigative site. There is no 
analysis planned by cen ter/investigative site.
5.4. Examination of Covariates , Other Strata and Subgroups
5.4.1. Covariates and Other Strata
The list of covariates which will be used indescriptive summaries and statistical ana lyses ., 
including the p rimary analysis are described in the table below. Additional covariates percent 
predicted FEV1 and baseline BMIwillbe explor edas a sensitivity analysis for the primary endpoint 
of the leg press strength only.
Category Details
Covariates Treatment, Day, Treatment x Day and Baseline 
Exploratory covariates Percent Predicted FEV1 and Baseline BMI
5.4.2. Examination of Subgroups
There is no subgroup analysis planned for this RAP , however, males and females will be analysed 
separately sin ce they have a different dose level .
5.5. Multiple Comparisons and Multiplicity
The primary comparison of interest sisthe change from baseline and percent change from baseline 
in maximum leg press strength following 1 repetition maximum (1 -RM). The key endpoi nt used for 
decision making purpose will be the percent change from baseline in maximum leg press strength .
This analysis will be conducted separately for each gender and the two analyses will be considered 
co-primary (i.e. both must be considered a succes s for the study to be successful), therefore no 
multiplicity adjustment is required. There will be no multiplicity adjustments for multiple endpoints or
multiple timepoints or multiple treatment comparisons .Analyses of other efficacy endpoints will not 
besubject to any multiplicity adjustment.
5.6. Other Considerations for Data A nalyses and Data Handling 
Conventions
Other considerations for data analyses and data handling conventions are outlined in the 
appendices:
Section Component
12.3 Appendix 3 : Assessment Windows
12.4 Appendix 4 : Study Phases 
12.5 Appendix 5 : Data Display Standards & Handling Conventions
12.6 Appendix 6 : Derived and Transformed Data
12.7 Appendix 7 : Reporting Standards for Missing Data
12.8 Appendix 8 : Values of Potential Clinical Importance
CONFIDENTIA L
200182
186. STUDY POPULA TION ANALYSES
6.1. Overview of Planned Stud y Population Analyses
The study population analyses will be mainly based on the All Participants population unless 
otherwise specified .
Study population analyses including analyses of subject’s disposition, protocol deviations,
demographic and baseline characteristics, prior and concomitant medications, and exposure and 
treatment compliance will be based on GSK Core Data Standards.  Details of the planned displays
are presented in Appendix 11 : List of Data Displays .
Table 2provides an overview of the planned study population analyses, with full details of data 
displays being presented in Appendix 11 :List of Data Displays.
Table 2 Overview of Planned Study  Population A nalyses
Display Type Data Display’s Generated
Table Listing
Randomisation
Randomisation Y [1]
Subject Disposition
Subjects Enrolled by Country and Site ID [6]Y Y
History of Rescreen ed Subjects [2]Y
Reasons for Screen Failure [2]Y Y
Subjects for Whom the Treatment Blind was Broken Y
Subject Disposition Y Y
Study Visit Dates  Y
Populations Analysed
Study Populations [2]Y Y
Protocol deviations
Important Protocol Deviati ons Y Y
Deviations leading to exclusion from PP Y Y
Inclusion and Exclusion Criteria Deviations Y
Demography
Demographic Characteristics [3]Y Y
Summary of Age Ranges [6]Y
Race & Racial Combinations [4]Y Y
Disease Staging Y
Medical Conditions , Concomitant Medications 
Medical Conditions (Current and Past) Y Y
CONFIDENTIA L
200182
19Exacerbation History Y
Alcohol History Y
History of Tobacco Use Y
Change of Smoking Status During the Study Y
Concomitant Medications Y Y 
HIV, Hepatitis B and C screening (Hepatitis C viral RNA 
PCR if Hepatitis C screening is positive)Y
Other 
IP Compliance [5]Y Y
NOTES:
Y = Display Generated, T = Tables, L = Listings, IP = Investigational Product
1. One listing of subjects randomised but not treated.
2. Screened population .
3. Age, sex, age group, ethnicity, race, weight, height , body surface area, percent predicted FEV1 and BMI (kg/m^2)
needs to be summarized. 
4. The five-high level FDA race categories and designated Asian subcategories will be summarised along with all 
combina tions of high-level categories which exist in the data. A by -subject listing of race will also be produced.
5. Dispensation information (dates, number of tablets dispensed , returned , taken and lost, compliance percentage, 
duration of treatment and treatment c umulative dose also will be included) .
6. Enrolled population 
CONFIDENTIA L
200182
207. EFFICA CY ANALYSES
7.1. Primary  Efficacy  Analy ses
7.1.1. Summary  Measure
The adjusted mean treatment difference for change and percent change from baseline in maximum 
leg press strength will be presented at D ays 28, 56 and 90.
7.1.2. Endpoint / Variables
The primary endpoint sarechange from baseline and percent change from baseline in maximum 
leg press strength following 1 repetition maximum (1 -RM). The key endpoint used for decision 
making purpose will be the perc ent change from baseline in maximum leg press strength.
7.1.3. Population of Interest 
The primary efficacy analyses will be based on the Analysis population. A supportive efficacy 
analyses will be based on the Per Protocol population.
7.1.4. Statistical A nalyses / Meth ods
Details of the planned displays are provided in Appendix 11 : List of Data Displays and will be 
based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 7.1.1 will be summarised using 
descriptive statistics, graphically presented (where appropriate) andlisted.
7.1.4.1. Statistical Methodology Specification
Endpoint s/ Variables
% change from baseline and change from basel ine in maximum leg press strength (Kg) 
following 1 repetition maximum (1 -RM) at Days 28, 56 and 90.
Model Specification
Change from baseline and percent change from baseline strength will be analyzed separately 
using mixed models repeated measures (MMRM ) adjusted for treatment, day, treatment x day, 
and baseline strength, with day as the repeated factor. 
Data falling into the analysis windows for day 28, day 56 and day 90 will be included in the 
model
The Kenward and Roger method for approximating the d enominator degrees of freedom and 
correcting for bias in the estimated variance -covariance of the fixed effects will be used.
An unstructured covariance structure for the R matrix will be used by specifying ‘type=UN’ on 
the REPEATED line.
In the event tha t this model fails to converge, the model will be re -fitted with other c ovariance 
structure s such as compound symmetry and one which gives the least Akaike's Information 
Criteria (AIC) from the fitted model will be used as the covariance structure.
The ana lysis will be conducted separately by gender 
CONFIDENTIA L
200182
21If there are any departures from the distributional assumptions for change or percentage 
change from baseline , the change of log -transformed data at post -baseline from log baseline 
will be the response variabl e, adjusted for treatment, log -transformed baseline strength, day 
and the interaction of treatment and day, with day as the repeated factor. The sensitivity 
analysis for the change from baseline and percentage change from baseline are the same.
Model Chec king & Diagnostics
Refer to Appendix 9 : Model Checking and Diagnostics for Statistical Analyses.
Model Results Presentation
For change and percent change from baseline, a djusted means ,corresponding standard error 
of means (SEs) and 9 0% confidence intervals will be pres ented for each treatment by day , 
together with estimated treatment differences (GSK 2881078 –Placebo) and the corresponding 
90% confidence intervals and p -value by day for both Analysis and Per Protoco l population . 
A line plot of the adjusted mean of change (and percentage change )from baseline as well as 
the 90% confidence interval over time ( day) for each treatment from the MMRM model will be 
provided for the analysis population.   
Log-transformed da ta results presentation
The estimated coefficients of the MMRM model will be transformed back (exponential 
transform). 
For each treatment, adjusted ratio of the post baseline value to the baseline value and 
corresponding 90% confidence intervals will be p resented by day . 
The adjusted treatment ratio of the ratio (postbaseline value/baseline value) between the two 
treatments with the corresponding 90% confidence interval be presented by day .  
The plot of adjusted ratio of the post baseline value to the ba seline value and its 90% 
confidence interval over time (day) for each treatment arm will be presented for the analysis 
population
Supportive Statistical Analysis -Bayesian
% change from baseline in maximum leg press strength following 1 repetition max imum (1 -
RM) at Days 28, 56 and 90 will be estimated by Bayesian analysis and separately by gender.
The posterior probability of treatment difference greater than 4% points, less than 9% points 
and greater than or equal to 9% points for each visit separate ly by gender.
Model Specification
Create indicator variables for the categorical effect: Treatment ( GSK2881078 vs. Placebo) 
and Day (day28, day56 and day90). 
For treatment, if treatment=placebo, then drug=0; if treatment= GSK2881078 , then drug=1;
Constru ct a linear model for each day(visit) in order to model within -subject observation 
covariance structures by multivariate normal (MVN) distribution in the MCMC procedure. For 
subject i on treatment j at Day k, the model can be written as: 
  PCHijk=β0 + β1 drug + β2 baseline + βd Dayk + βdk drug* Dayk +εijk       εijk ~ N(0, σ2);
where PCH refers to percentage change from baseline and Dayk for k=1, 2, 3 represent days 
28, 56 and 90, respectively, and are indicator variables, which are intrinsically formed wi thin 
CONFIDENTIA L
200182
22PROC MCMC from the design matrix. The last element, Day3, is excluded by setting it to 0 in 
the PARMS statement.
(β1+ βd1), (β1+ βd2), are the estimated treatment differences ( GSK2881078 vs. Placebo) at 
Day 28, Day 56 respectively. β1 is the estimate d treatment difference ( GSK2881078 vs. 
placebo) at Day 90
Reformat the input data in the way that all repeated measurement sfrom a subject arein one 
row 
Set seed=123456 with the simulation size of 500000 , 5000 burn-in iterations . The simulation 
size and number of burn -in iterations could be updated during the convergence check.
The non -informative priors (normal (0, var=1e6)) will be used for the regression parameters 
The3-dimension inverse wishart scale matrix will be used as the prior of the covarianc e 
matrix .The degrees of freedom will be 3 and the positive definite scale matrix will be an 
identity matrix .
Multivariate normal (MVN) distribution will be specified to model all repeated measurements
Count the proportion at Day90 where β1 greater than 4%points , less than 9% points and 
greater or equal to 9% points respectively from the posterior probability distribution simulation .
Similarly, Count the proportion at Day28 and Day56 where (β1+ βd1), (β1+ βd2) are separately
greater than 4% points , less th an 9% points and greater or equal to 9% points respectively 
from the posterior probability distribution.
For calculating the posterior adjusted least square mean and corresponding difference , use 
the coefficient of L -matrix of the covariates from the MMRM analysis mentioned in Section 
7.1.4.1
Model Checking & Diagnostics
Refer to Appendix 9 : Model Checking and Diagnostics for Statistical Analyses.
Model Results Presentation
n, posterior adjusted least square mean and 90% highest posterior density (HPD) interval, the 
adjusted treatment difference and its 90% HPD credible interval and standard deviation for the 
posterior adjusted least square mean and difference.
The treatment difference (GSK 2881078 –Placebo) for the percentage change from baseline at 
each visit (Day 28, Day 56 and Day 90 )>4percentage points , <9percentage points and≥ 9
percentage points will be reported based upon the simulation results from the posterior 
probability model .
7.2. Secondary  Efficacy A nalyses
7.2.1. Endpoint / Variables
The secondary endpoints are:
Change and % change from baseline in appendicular, and total lea n mass as assessed by 
Dual-energy X -ray Absorptiometry (DXA).
Change from baseline in total Short Physical Performance Battery (SPPB) score, times for 
chair rise and 4 m gait speed.
CONFIDENTIA L
200182
23Change and % change from baseline in Constant Work Rate (CWR) duration fro m 
endurance shuttle walking test. 
Change and % change from baseline in peak performance from incremental shuttle 
walking test.
Change in PROactive endpoints (individual components (difficulty and amount score) and 
total score).
Change from baseline in COP D Assessment Test (CAT).
Responder of COPD Assessment Test (CAT). 
Change in St George Respiratory Questionnaire (SGRQ) total score and domain scores 
derived from SGRQ -c raw score.
Responder of St George Respiratory Questionnaire (SGRQ) defined by the tota l score.
Change from baseline in forced expiratory volume in 1 second (FEV1).
Patient Global Impression of Change (PGIC).
Patient Global Rating of Severity (PGRS).
Change from baseline in Sniff nasal inspiratory pressure (SnIP).
Change in physical activity measures as assessed via an accelerometer.
7.2.2. Summary  Measure
The adjusted mean treatment differences ( GSK2881078 –Placebo) for the following endpoints will 
be presented:
Change and % change from baseline in appendicular, and total lean mass as assessed by 
Dual-energy X -ray Absorptiometry (DXA) at Days 28, 56 and 90.
Change from baseline in total Short Physical Performance Battery (SPPB) score, times for 
chair rise and 4 m gait speed at Days 28, 56 and 90. 
Change and % change from baseline in Constant Work Rate (CWR) duration from 
endurance shuttle walking test at Day 90.
Change and % change from baseline in peak performance from incremental shuttle 
walking test at Day 90.
Change from baseline in PROactive endpoints at Days 56 and 90. (individual components 
and total score).
Change from baseline in COPD Assessment Test (CAT) score at Days 56 and 90. 
Change from baseline in St George Respiratory Questionnaire (SGRQ) total score and 
domain scores derived from SGRQ -c raw scores at Days 90.
The responder analysi s between GSK2881078 and Placebo ( GSK2881078 / Placebo) for the 
following endpoints will be explored 
Odds ratio between treatment groups for the COPD Assessment Test (CAT) responder at 
Days 56 and 90. 
Odds ratio between treatment groups for the St George Respiratory Questionnaire 
(SGRQ) responder defined by the total score derived from SGRQ -c raw scores at Days 90.
The descriptive summaries will be reported for the following endpoints 
Change from baseline in forced expiratory volume in 1 second (FEV1).
CONFIDENTIA L
200182
24Frequency and percentages of Patient Global Impression of Change (PGIC) responses.
Frequency and percentages of Patient Global Rating of Severity (PGRS) responses.
Change from baseline in Sniff nasal inspiratory pressure (SnIP).
Change in physical activity m easures as assessed via an accelerometer.
7.2.3. Population of Interest 
The secondary efficacy analyses will be based on the Analysis Population. Thedecision -making
endpoints PROactive endp oint, SGRQ , SPPB (time for repeated chair rise endpoint) and constant 
work rate (CWR) duration from endurance shuttle walking test will be also analysed base don the 
Per Protocol population .
7.2.4. Statistical A nalyses / Methods
Details of the planned displays are provided in Appendix 11 : List o f Data Displays and will be 
based on GSK data standards and statistical principles.
Unless o therwise specified, endpoints / variables defined in Section 7.2.1 will be summarised using 
descriptive statistics, graph ically presented (where appropriate) and listed.
7.2.4.1. Statistical Methodology  Specification
Secondary Efficacy Endpoint / Variables –Multiple Post -baseline Visit
Change and % change from baseline in appendicular, and total lean mass as assessed by 
Dual-energy X-ray Absorptiometry (DXA) at Days 28, 56 and 90.
Change from baseline in total Short Physical Performance Battery (SPPB) score, **time for 
repeated chair rise and 4 m gait speed at Days 28, 56 and 90.
Change from baseline (Day 1) in *PROactive endpoints (individual components (difficulty and 
amount score) and **total score) at Days 56 and 90.
Change from baseline in COPD Assessment Test (CAT) score at Days 56 and 90. 
*A physical activity monitor will be worn for 7 days after the Day -9 visit (Day 1), for 7 days after the Day 
56 visit (Day 56), and for 7 days following the day 80 visit (Day 90).
**Bayesian analysis will be performed only for the endpoints change from baseline of PROactive total 
scores and change from baseline in the time for repeated chair rise. The posterior probability of 
treatment difference greater than 3 points and less than 6 points for PROactive total scores and greater 
than 1.3 seconds and less than 1.7 seconds for time for repeated chair rise will be estimated for each 
visit separa tely by gender .
Model Specification
Treatment difference ( GSK2881078 –placebo) at each visit on change from baseline or 
percentage change from baseline (as appropriate) will be analysed using mixed models 
repeated measures (MMRM) models as what was desc ribed for the primary efficacy endpoint 
in Section 7.1.4.1 .The analyses will be based on the analysis population for all endpoints 
additionally the endpoints PROactive and SPPB will be analysed for p er-protocol population as 
well.
If there are any departures from the distributional assumptions for change or percentage 
change from baseline, the change of log -transformed data at post -baseline from log baseline 
will be the response variable, adjusted fo r treatment, log -transformed baseline value , day and 
CONFIDENTIA L
200182
25the interaction of treatment and day, with day as the repeated factor.
A Bayesian approach will also be employed for the change from baseline in PROactive weekly 
total score and time for repeated chair r ise to estimate the treatment difference in the change 
from baseline for analysis population , following the similar procedures described in Section 
7.1.4.1 . for the primary efficacy endpoint analysis. For calculating the posterior adjusted least 
square mean and corresponding difference, use the coefficient of L -matrix of the covariates 
from the corresponding frequentist MMRM analysis .
Model Checking & Diagnostics
Refer to Append ix 9: Model Checking and Diagnostics for Statistical Analyses.
Model Results Presentation
For change and percent change from baseline, adjusted means and corresponding standard 
error of means (SEs) and 90% confidence intervals will be pre sented for each treatment by 
gender and then by time, together with estimated treatment differences ( GSK2881078 –
Placebo) and the corresponding 90% confidence intervals for MMRM estimation.
In case of the violation of assumptions in MMRM analysis, adjuste d mean for ratio to baseline 
and 90% confidence intervals will be presented for each treatment by gender and then by time, 
together with adjusted treatment ratio of the ratio (postbaseline value/baseline value) between 
the two treatments with the correspon ding 90% confidence interval be presented by day .
A line plot of the adjusted mean change from baseline or percentage change from baseline (as 
appropriate) as well as 90% confidence intervals over time (day) for each treatment by gender 
from the MMRM model will be provided for the analysis population. In case of violation of 
assumption in MMRM analysis, the adjusted mean for ratio to baseline and corresponding 90% 
confidence interval will be plotted.           
For the Bayesian analysis, n, posterior adjuste d least square mean and 90% highest posterior 
density (HPD) interval, the adjusted treatment difference and its 90% HPD credible interval and 
standard deviation for the posterior adjusted least square mean and difference will be reported 
along with the est imated probabilities.    
For the Bayesian analysis for PROactive weekly total score, the probability of treatment 
difference ( GSK2881078 -placebo) greater than 3 points and less than 6points will be 
estimated through the simulations of the posterior proba bility distribution. Similarly, for the 
Bayesian analysis for time for repeated chair rise, the probability of treatment difference 
(GSK2881078 -placebo) greater than 1.3 seconds and less than 1.7 seconds will be estimated 
through the simulations of the pos terior probability distribution.
Secondary Efficacy Endpoint / Variables –Categorical Variable
Odds ratio of COPD Assessment Test (CAT) responder at Days 56 and 90. 
Odds ratio of St George Respiratory Questionnaire (SGRQ) responder derived by the total 
score at Days 90.
Model Results Presentation
The number of responders, odds ratio and associated 90% exact confidence intervals between 
treatment groups ( GSK2881078 vs. placebo) will be reported for CAT and SGRQ responder 
analysis by gender.
CONFIDENTIA L
200182
26Secondar y Efficacy Endpoint / Variables –Single Post -baseline Visit
Change and % change from baseline in Constant Work Rate (CWR) duration *from endurance 
shuttle walking test at Day 90.
Change and % change from baseline in peak performance from incremental shut tle walking 
test at Day 90.
Change from baseline in St George Respiratory Questionnaire (SGRQ) total score *and 
domain scores derived from SGRQ -c raw scores at Days 90.
*Bayesian analysis will be performed only for the endpoints change from baseline of Con stant Work 
Rate (CWR) duration and change from baseline of SGRQ total score. The posterior probability of 
treatment difference greater than 36 seconds and less than 48 seconds for Constant Work Rate (CWR) 
duration and greater than 2 points and less than 4 points SGRQ total score will be estimated.
Model Specification
Treatment difference ( GSK2881078 –placebo) in the change from baseline and percentage 
change from baseline at Day 90 will be analysed using ANCOVA where baseline and 
treatment will be includ ed as the independent variables in the model. Each gender will be 
analysed separately. The analyses will be based on the analysis population for the endpoints 
CWR duration, peak performance from incremental shuttle walking test and SGRQ total score
additio nally the endpoints CWR duration and SGRQ total score will be analysed for per -
protocol population as well.
If there are any departures from the distributional assumptions, the change of log -transformed 
data at post -baseline from log baseline will be the response variable, adjusted for treatment, 
and log -transformed baseline value .
A Bayesian approach will also be conducted to estimate the treatment difference in the change 
from baseline at Day 90 for CWR duration and change from baseline SGRQ total score for the 
analysis population , following the similar procedures described in Section 7.1.4.1 . for the 
primary efficacy endpoint analysis with the model being constructed as below:
Create indicator varia bles for the categorical effect: Treatment ( GSK2881078 vs. Placebo). 
For treatment, if treatment=placebo, then drug=0; if treatment= GSK2881078 , then drug=1;
For subject i on treatment j, the model can be written as: 
                  CHij=β0+ β1drug + β 2base+ +ε ij 
where CH refers to the change from baseline at Day 90; base means baseline assessment; 
drug=0 when treatment is placebo and drug=1 for GSK2881078 treatment; ε ij ~ N(0, σ 2);
β1is the estimated treatment difference ( GSK2881078 vs. placebo) at Day 90; 
Set seed=123456 with the simulation size of 200000 and 5000 burn -in iterations; the sample 
size and the number of burn -in iterations could be updated during the convergence check.
The non -informative priors (normal (0, var=1e6)) wi ll be used for the regression parameters 
β0, β1, and β 2.and the prior for variance σ 2will be the inverse gamma (0.01, scale=0.01)
For calculating the posterior adjusted least square mean and corresponding difference, use 
the coefficient of L -matrix of th e covariates from the corresponding ANCOVA analysis 
Model Checking & Diagnostics
Refer to Appendix 9: Model Checking and Diagnostics for Statistical Analyses.
CONFIDENTIA L
200182
27Model Results Presentation
For change and percent cha nge from baseline, adjusted means and corresponding standard 
error of means (SEs) and 90% confidence intervals will be presented for each treatment at Day 
90, together with estimated treatment differences ( GSK2881078 –Placebo) and the 
corresponding 90% co nfidence intervals through ANCOVA model .
In case of the violation of assumptions in ANCOVA analysis, adjusted mean for ratio to 
baseline and 90% confidence intervals will be presented for each treatment by gender, 
together with adjusted treatment ratio of the ratio (postbaseline value/baseline value) between 
the two treatments with the corresponding 90% confidence interval be presented.
For the Bayesian analysis, n, posterior adjusted least square mean and 90% highest posterior 
density (HPD) interval, the a djusted treatment difference and its 90% HPD credible interval and 
standard deviation for the posterior adjusted least square mean and difference will be reported 
along with the estimated probabilities.    
For the Bayesian analysis for CWR duration, the p robability of treatment difference 
(GSK2881078 -placebo) greater than 36 seconds and less than 48 seconds will be estimated 
through the simulations of the posterior probability distribution. Similarly, for the Bayesian 
analysis for SGRQ total score, the pro bability of treatment difference ( GSK2881078 -placebo) 
greater than 2 points and less than 4 points will be estimated through the simulations of the 
posterior probability distribution.
Secondary Efficacy Endpoint / Variables –Descriptive Summary
Forced expiratory volume in 1 second (FEV1) at Days 1, 56 and 90.
Patient Global Impression of Change (PGIC) at Days 14, 28, 56 and 90.
Patient Global Rating of Severity (PGRS) at Days 1 and 90.
Sniff nasal inspiratory pressure (SnIP) at Days 1, 56 and 90.
Physic al activity measures as assessed via an accelerometer at Days 1, 56 and 80.
Summary Results Presentation
Baseline , each postbaseline visit and change from baseline , will be descriptively summarized by 
treatment group for endpoints: weekly average steps, vector magnitude unit/wear time and 
moderate/vigorous activity duration measures via an accelerometer .The number of subjects with 
the eligible days i.e. wear duration more than 8 hours for at least 4 days, the average eligible days 
for those subjects and average wear duration (minutes) during the eligible days will be 
summarized.
Baseline, each postbaseline visit and change from baseline, will be descriptively summarized by 
treatment group for original FEV1 (L) and percentage predicted FEV1 and maximum Snl P.
In addition, a box plot will be prepared for the change from baseline for FEV1 and Sn IPatthe post -
baseline visits.
For the categorical endpoints, PGRS and PGIC, the count and percentage will be summarized by 
category and treatment for each visit separ ately by gender.
CONFIDENTIA L
200182
287.3. Exploratory  Efficacy  Analyses
7.3.1. Endpoint / Variables
The exploratory endpoints that will be analy sed are:
Changes from baseline in handgrip strength.
7.3.2. Summary  Measure
Descriptive summary of baseline assessments, post -baseline assessments and change from 
baseline for handgrip strength .
Changes from baseline in size of inspiratory muscles and/or other organs will not be analyzed in 
this report because there is no data collected. In addition, exit interview data will be reported 
separately, thus the analysis of the endpoint ‘Gain further insights into the participants’ experience 
with study treatment and their participation in the trial’ will not be performed in this RAP. The 
adherence to the exercise program (daily physical activity and thrice -weekly strengthening 
exercises) will not be explored in this RAP. 
7.3.3. Population of Interest 
The exploratory efficacy analyses will be based on the Analysis population, unless otherwise 
specified.
7.3.4. Statistical A nalyses / Methods
Details of the planned displays are provided in Appendix 11 : List of Data Displays and will be 
based on GSK data standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 7.2.1 will be summarised using 
descriptive statistics, graphically presented (where appropriate) and listed.
7.3.4.1. Statistical Methodology  Specification
Endpoint / Variables
 Changes from baseline in handgrip strength.
Summary Results Presentation
The handgrip strength of left hand and right hand will be separately summarized for baseline, 
Day 90 and change from baseline at Day 90 by treatment for each gender separately
CONFIDENTIA L
200182
297.3.4.2. Other A nalyses
An exploratory analysis will be performed on the analysis population to identify how the 
change from baseline of PROactive total and domain scores chang esover the responses 
of PGIC questionnaire. Thisrelationship between PGIC levels and change from baseline in 
PROactive total and domains scores will be explored by a descriptive summary table for 
the visits Day 56 and 90. This comparison will be by gender (males, females and overall 
(male + female)) and not with respect to treatment. Along with the seven levels of PGIC, 
the pooled categories “Much worse and Worse ” and “Better and Much Better ” willalso be 
summarized.
A sensitivity analysis has to be performed to identify the influence of center  onthe 
primary analysis. The primary analysis of percentage change from baseline for leg press 
hasto perform by r emoving the subjects recruited from the center for the analysis 
population .This is the analysis supporting the SPOOS ( (Significant Payments of Other 
Sorts) impact analysis. 
Plots to be generated in R- shiny A pp
Shiny is an open R package from RStud io, which provides a web application framework to create 
interactive web applications (visualization) called “Shiny apps”. Shiny combines the computational 
power of R with the interactivity of the modern web. Shiny web apps can be deployed locally or on 
the web through tools such as RStudio Connect. 
The below mentioned plots will be generated in the R -shiny app at SAC. These displays will then
be sent for clinical review. From the generated plots only the clinically important ones will be 
identified and ad ded to the CSR and will be considered post hoc analyses. These plots will be 
generated for the analysis population.
Absolute, Change and percent change from baseline in the leg press strength and change 
from baseline in constant work rate (CWR) duration fr om endurance shuttle walking test 
and peak performance from incremental shuttle walking test versus baseline SPPB 
categories will be plotted (box -plot) by treatment group for each gender separately. The 
box-plots for both the treatment groups will be prese nted in one plot for one gender; then 
repeat for the other gender. 
The relationship between absolute, change and percent change from baseline at Day 90 in 
the leg press strength , change from baseline in constant work rate (CWR) duration from 
endurance shuttle walking test at Day 90  and peak performance from incremental shuttle 
walking testat Day 90 versus baseline PROactive scores for all the domains score as well 
as the baseline average daily steps via an accelerometer will be explored by the scattered
plots by treatment group for each gender. Baseline scores will be the x-axis and absolute 
or change from baseline or percent from baseline at Day 90 in the leg press strength and 
shuttle walk tests separately will be the y -axis 
Mean absolute, change from baseline and percentage change from baseline in leg press 
strength, change from baseline in appendicular and total lean mass, constant work rate 
(CWR) duration from endurance shuttle walking test, peak performance from incremental 
shuttle walking test, to tal SPPB score, hand grip, SGRQ (all domains ) and PROactive (all 
domains)  will be plotted by treatment group for each gender, where descriptive mean for 
absolute, change from baseline and percentage change from baseline for the respective 
endpoints will b e the Y -axis in each plot and X -axis will be the visits.
PPD
PPD
CONFIDENTIA L
200182
308. SAFETY ANALYSES
The safety analyses will be based on the safety population and actual treatment group , unless 
otherwise specified. Data for male and female subjects will be analysed separately.
8.1. Adverse Events A nalyses
Adverse events analyses including the analysis of adverse events (AEs), Serious (SAEs) and other 
significant AEs will be based on GSK Core Data Standards. The AE text recorded in the eCRF will 
be coded using the Medical Dictionary for Re gulatory Activities (MedDRA version 22.0 ) and will be 
reported using the primary System Organ Class (SOC) and Preferred Term (PT). Results will be 
displayed irrespective of treatment phase   in the order of decreasing frequency, both across SOC 
and within S OC.The details of the planned displays are provided inAppendix 11 : List of Data 
Displays .
For those displays with maximum intensity, if AEs arereported more than once by a subject, the 
most severe intensity will be included. An adverse event will be considered as a common adverse 
event if it occurs in more than one patient in either gender.
8.2. Adverse Events of Special Interest Analyses
The table in Section 12.6. 3(“Safety”) presents the Adve rse Events of Special Interest (AESI) and 
the group sof terms that they comprise . AESI which are not standardized MedDRA queries (SMQs) 
comprise a selection of PTs defined by GSK. The final listof AESIs , and the PTs that contribute to 
each of the AESIs , will be provided by Safety and Medical Governance ( SMG ),using the MedDRA 
version current at the time of reporting. This list will be finalized prior to unblinding the database. 
Changes to the MedDRA dictionary may occur between the start of the study and the time of 
reporting. Furthermore, emerging data from on -going studies may highlight additional AESI . 
Therefore, the list of AESI, and the terms included for each AESI ,will be based on the safety 
review team (SRT) agreements in place at the time of repor ting. The details of the planned displays 
are provided in Appendix 11 : List of Data Displays .
8.3. Clinical Laboratory  Analyses
Laboratory evaluations including the analyses of Chemistry laboratory tests, Haematology
labora tory tests, Urinalysis, Lipids and liver function tests will be based on GSK Core Data 
Standards. The details of the planned displays are inAppendix 11 : List of Data Displays .
A line plot of the mean change from base line(latest pre -dose value including unscheduled visits )
as well as +/-standard error over time (day) for each treatment by gender will be plotted for below 
mentioned sex hormones and metabolic analytes .      
Sex / Reproductive Hormones
Testosterone, Fr ee Testosterone, Sex hormone -binding globulin (SHBG), Follicle -stimulating 
hormone (FSH), Luteinizing hormone (LH) and Prostate specific antigen (PSA).
CONFIDENTIA L
200182
31Metabolic Analytes
Total Cholesterol, LDL Cholesterol, HDL Cholesterol, Triglyceride, Glucose and HbA1c.
8.4. Other Safety  Analyses
The analyses o fnon-laboratory safety test results including ECG sand vital sign swill be based on
GSK Core Data Standards , unless otherwise specified. The details of the planned displays are 
presented in Appendix 11 : List of Data Displays .
A listing of changes from baseline in hepatic, prostate (males) and cardiac structure and function 
assessed via MRI scan will be presented as an exploratory analysis. 
Biomarkers will be summarized descriptivel y. The reproductive tissue biomarkers and bone 
markers to summarize are given below.
Reproductive Tissue Biomarkers
Luteinizing hormone, Follicle stimulating hormone, Total testosterone, Free testosterone 
(calculated) in males and female, Estradiol (female s), Dihydrotestosterone, Sex hormone binding 
globulin and Prostate specific antigen (PSA) (males ).
Bone Biomarkers
Procollagen type I N propeptide (s -PINP) and C -terminal telopeptide of type I collagen (s -CTX).
CONFIDENTIA L
200182
329. PHA RMACOKINETIC ANALYSES
PK concentration rel ated summar ieswill be presented. No PK parameters will be derived in this 
RAP. The PK parameters for the Study will be derived as a part of Population Pharmacokinetic 
(POPPK) analyses. The POPPK RAP will include the detailed population PK analysis and res ulting 
derived PK parameters including Cmax and AUC over dosing interval. 
9.1. Secondary  Pharmacokinetic A nalyses
9.1.1. Summary  Measure
Pharmacokinetic concentration data will be presented in graphical and tabular form and will be 
summarized descriptively by gender.
9.1.2. Population of Interest 
The secondary pharmacokinetic analyses will be based on the Pharmacokinetic population, unless 
otherwise specified.
9.1.3. Statistical A nalyses / Methods
Details of the planned displays are provided in Appendix 11 : List of Data Displays and will be 
based on GSK Data Standards and statistical principles.
9.1.3.1. Statistical Methodology  Specification
Plasma concentration time data will be descriptively summarized bythe 3 sampling intervals (pre
dose, 1 -4h inter val and 5 -8 h intervals) by visit andalso listedbytreatment group for each gender . 
10. POPULA TION PHARM ACOK INETIC (POPPK) 
ANALYSES
A population PK analysis will be conducted on the final data. The timeline for these analyses will be 
independent of the ana lysis described in this RAP. To support this analysis a NONMEM -specific 
data file will be generated, the analysis approach and specifications are detailed in the POP PK 
Data Analysis Plan by CPMS.
To support this analysis two NONMEM -specific data files wil l be generated by S&P using pre -
defined formatted datasets provided by CPMS. The first formatted dataset will focus on the PK 
data and all relevant covariates. The second dataset will contain the time dependent efficacy and 
safety endpoints.   
CONFIDENTIA L
200182
3311. REFERENCES
Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and 
treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Resp J 2004 23: 
932-946
IMI PROACTIVE IN COPD DAILY AND CLINICAL INSTRUMENTS D -PPAC and C -PPAC USER 
GIDE (14June2016)
Jones, PW and Forde Y (2016). St. Georges Respiratory Questionnaire for COPD Patients 
Manual, version 1.3.
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL et al. Multi -ethnic reference values for 
spirometry for the 3-95 year age range: the global lung function 2012 equations. Eur Resp J. 2012; 
40: 1324 -1343
CONFIDENTIA L
200182
3412. APPENDICES
12.1. Appendix 1: Protocol Deviation Management and Definitions 
for Per Protocol Population
12.1.1. Exclusions from Per Protocol Population
The criteria for subject exclusion from the Per Protocol population are based on ‘the Protocol 
Deviation Specification version 2.0 -31August 2018 ’. Refer to the latest version of the rules 
document prior to finalisation of the per protocol population.
The following criteria define the protocol deviations Potential protocol deviations leading to 
exclusion from PP population will be reviewed by the study team to confirm that they meet these 
criteria.  This review will occur before the clinical database has been frozen for analysis. N ote: 
None of the protocol deviations need the data unblinding to take the decision whether the subject 
data to be excluded from analysis or not. So,the protocol deviation meeting post unblinding won’t 
be conducted.
A subject meeting any of the following c riteria will be excluded from the Per Protocol population:
Number Exclusion Description
01 Inclusion #1 –Subject not 50 -75 years of age inclusive
02 Inclusion # 3 –Did not have Confirmed Diagnosis of COPD
03Inclusion #4 –SPPB: Score of “0” on any com ponent of the SPPB orTimed Chair Stand 
Score is <1 and >3
04 Inclusion #5 –BMI not within 18 -32kg/m2 (inclusive)
05Inclusion #6 –not current smokers orformer smokers with a cigarette smoking history of 
<10 pack years
06 Exclusion #1 -7–Prohibit edMedical Conditions
07 Exclusion #8 -10 –Prohibited Treatments
08 Exclusion # 11 –Prohibited Prior/Current Clinical Study Experience
09 Exclusion #12 -13 –Key laboratory tests out of range
10 Exclusion #14 –ECG values above ranges (QTc > 480, QTcB/F > 450)
11 Exclusion #15 –Positive HIV antibody test
12Any other deviations from inclusion/exclusion criteria which could impact the efficacy 
assessment.
13Experience an exacerbation , which need edtreatment with steroids during the treatment 
phase of the study
14Notcomplet ingthe Day 80 PROactive endpoint ,Week 13 (Day 90) lean mass and all of the 
functional assessments (leg press strength, peak performance from Incremental shuttle 
walking test, Constant Work Rate (CWR) duration from endurance shut tle walking test, total 
SPPB score and handgrip strength ).
15 Permanent discontinuation of the treatment during the study treatment period (This check 
must will be performed by Statistics and Programming).
CONFIDENTIA L
200182
3512.2. Appendix 2: Schedule of A ctivities
12.2.1. Protocol De fined Schedule of Events
Procedure Screening 
V1
(up to 30 
days before 
Day 1)V2
Day -9Treatment Period (13 weeks) Follow -
up2
V9
(42 days 
post last 
dose)Notes
V3
Baseline 
Day 1V4
Day 
14V5
Day 
28V6
Day 
56V7
Day 
80V8
Last 
dose 
90Unscheduled 
visit 1
Visit window (days) -30 to -11-11 to 
-7-2 to day 
112 -
1624 –
3252-
6076 -
8485 –
91126-140There should be an 
attempt to conduct all 
assessments for a visit within a 
single day 3.
Informed consent XObtained prior to performin g any 
study -related procedures.
Inclusion and exclusion criteria X
Demography/ medical/medication/ 
drug/ alcohol history/ PD disease 
stagingX
Full physical examination X X X
Brief physical exam X X X X X
12-lead ECG X X X X X X X X
Vital signs X X X X X X X X
HIV, Hepatitis B and C screening XIf test otherwise performed within 3 
months prior to first dose of study 
treatment, testing at screening is 
not required
CONFIDENTIA L
200182
36Procedure Screening 
V1
(up to 30 
days before 
Day 1)V2
Day -9Treatment Period (13 weeks) Follow -
up2
V9
(42 days 
post last 
dose)Notes
V3
Baseline 
Day 1V4
Day 
14V5
Day 
28V6
Day 
56V7
Day 
80V8
Last 
dose 
90Unscheduled 
visit 1
Hepatitis C viral RNA PCR XIf evidence of Hepatitis C 
antibodies at screening visit, then 
Hepatitis C viral RNA PCR 
required to exclude active infection. 
This sample is not needed if 
Hepatitis C screening is negative.
Haematology (Full blood count)/ 
Clinical Chemistry (Creatinine, urea 
and electrolytes, liver function tests, 
glucose) X X X X X X XXParticipants should fast overnight 
for at least 8 hours prior to 
collection of these samples. 
HbA1c X X
hsCRP, Fibrinogen X X X
25-OH Vitamin D Total, 25 -OH 
Vitamin D2, 25 -OH Vitamin D3X X X
Lipid panel X X X X X X X
Genetic sample XObtain after participant is 
randomized. Informed consent to 
obtain the genetics sample must 
be obtained before collecting a 
sample.
Pharmacokinetic sampling X4X4,5X6X4XTimes of dose administration for 
the two doses immediately 
preceding a PK sample should be 
accurately recorded.
Reproductive Tissue Biomarkers X X X X X
PSA X X X X X XFor male participants only
Bone Biomarkers X X X X
CONFIDENTIA L
200182
37Procedure Screening 
V1
(up to 30 
days before 
Day 1)V2
Day -9Treatment Period (13 weeks) Follow -
up2
V9
(42 days 
post last 
dose)Notes
V3
Baseline 
Day 1V4
Day 
14V5
Day 
28V6
Day 
56V7
Day 
80V8
Last 
dose 
90Unscheduled 
visit 1
Exploratory Biomarkers X X X X X X
Urinalysis X X X X X
DXA X X X X X X
Spirometry X X X XFollow ATS/ ERS guidelines [ Celli, 
2004 ] and Quanjer reference 
equation [Quanjer , 2012 ].  
Sniff Nasal Inspiratory Pressure X X X X
Leg strength X X X X X X
Handgrip strength X X X
Short Physical Performance Battery X X X X X X
Incremental Shuttle Walk TestXX XPractic e incremental shuttle walk 
test conducted at day -9
Endurance Shuttle Walk Test X X
COPD Assessment Test X X X
St George Respiratory 
Questionnaire COPD (SGRQ -c)X X
Patient Global Rating of Severity X X
Patient Globa l Impression of Change X X X X X
Daily PROactive Physical Activity in 
COPD instrument and Physical 
Activity MonitorX X7X X7Physical activity monitor dispensed 
at screening, day -9, day 56 and 
day 80 visits. Activity monitor 
should be worn f or 7 days at each 
timepoint and returned at the next 
visit.
Monitored home exercise program X X =============== XParticipants will receive training for 
the exercise program at Day -9, 
and will formally begin exercises 
on day 1
Patient exit intervie w X
CONFIDENTIA L
200182
38Procedure Screening 
V1
(up to 30 
days before 
Day 1)V2
Day -9Treatment Period (13 weeks) Follow -
up2
V9
(42 days 
post last 
dose)Notes
V3
Baseline 
Day 1V4
Day 
14V5
Day 
28V6
Day 
56V7
Day 
80V8
Last 
dose 
90Unscheduled 
visit 1
Randomization XAll Baseline assessments must be 
obtained prior to randomization. 
Study treatment provided to 
participantX X XThe subject should take their first 
dose of study treatment in the clinic 
after randomization.
Study treatment X ================ XParticipants should dose study 
treatment in the clinic at each clinic 
visit during the treatment period.
Study treatment accountability by 
study site X X X X XThe required counting of pills by 
site staf f to check compliance is 
not considered redispensing the 
study medication.
AE review X =============================  X
SAE review X =============================  X
Concomitant medication review X =============================  X
Optional sub-study measures
Cardiac and liver MRI (additionally 
prostate MRI in males)X8X8MRI is an optional assessment 
undertaken at participating centres 
only.
ECG= Electrocardiogram; HIV= Human Immunodeficiency Virus; PK= Pharmacokinetic; PSA= Pros tate Specific Antigen; DXA= Dual -energy X -ray 
Absorptiometry; AE= Adverse Event; SAE= Serious Adverse Event.
1.An unscheduled clinic visit may occur at any time if the investigator believes an unscheduled visit is clinically warranted. Individual listed 
asse ssments are optional and are performed as needed to follow unresolved findings of clinical concern. Note: The “Unscheduled vi sit” case 
report form (CRF) form should be completed as soon as possible following the Unscheduled visit.
CONFIDENTIA L
200182
392.As stated in Section 8.2, if a participant decides to withdraw or is withdrawn by the responsible physician, the reasons for withdrawal and the 
results of any relevant tests will be recorded in the CRF and the planned safety follow -up proce dures will be performed, where possible. These 
include physical examination, 12 -lead ECG, vitals, blood tests, urinalysis and concomitant medication review as listed for the follow -up visit (V9).
3.Attempt to conduct all visits within a single day however th e baseline (day 1) and last dose (day 90) visits may require subjects to visit the study 
centre on more than one day in order to complete MRI and DXA scans, and possibly other assessments. These scans, and any othe r 
assessments, should be conducted within the specified visit window, and prior to randomization at the baseline visit. Further details on the 
suggested order of assessments will be given in the SRM.
4.Take PK sample prior to dosing in the clinic
5.Take PK sample 1 -4 hours post -dose (sites should try and ensure that a range of times are sampled within this time window for different 
participants, i.e. all PK samples should not be taken at 1 hour post dose or 2 hours post dose).
6.Take PK sample 5 -8 hours post -dose (as above, sites should try and ensure th at a range of times are sampled within this time window for 
different participants).
7.At V3 Baseline Day 1 and V8 Last dose 90, the patients will return the Daily PROactive Physical Activity in COPD Instrument a nd the Physical 
Activity Monitor to the site. Patients will not be dispensed the Daily PROactive Physical Activity in COPD Instrument and the Physical Activity 
Monitor at the end of these visits.
8.All MRI Scans (Cardiac MRI, Liver MRI and, if applicable, Prostate MRI) should preferably be scheduled on the same day. Acquisition of the 
Cardiac MRI should be prioritized above the other two scans if it becomes unfeasible to perform all the MRI sc an.
The following points must be noted: 
If assessments are scheduled for the same nominal time, THEN the assessm ents should occur in the following order:
i.vital signs
ii.12-lead ECG
iii.blood draws.  
Note: The timing of the assessments should allow the blood draw to occur at the time specified in the SoA .
CON FIDENTIA L
200182
4012.3. Appendix 3: A ssessment Windows
12.3.1. Defin itions of Assessment Windows f or Analy ses
Analysis 
Set / 
DomainParameter      
(if 
applicable)Protocol Window Target Analysis Window Analysis 
Timepoint Beginning 
TimepointEnding
TimepointBeginning 
TimepointEnding 
Timepoint
All All Day -30 Day -11 Day -
30 to -
11Day -60 Day -12 Screening /Visit 
1
All All Day -11 Day -7 Day -9 Day -11 Day -5 Visit 2
All All Day -2 Day 1 Day 1 Day -4 Day 1 Visit 3, Day 1
All All Day 12 Day 16 Day 14 Day 1 0 Day 1 8 Visit 4, Day 14
All All Day 24 Day 32 Day 28 Day 2 2 Day 3 4 Visit 5, Day 28
All All Day 52 Day 60 Day 56 Day 5 0 Day 6 2 Visit 6, Day 56
All All Day 76 Day 84 Day 80 Day 76 Day 84 Visit 7, Day 80
All All Day 85 Day 91 Day 90 Day 85 Day 9 7 Visit 8, Day 90
All All Day 126 Day 140 Day 
132Day 126 Day 140 Follow -Up, Day 
132
For schedule d visits the analysis visit would equal the nominal visit irrespective of the 
assessment date and irrespective of whether that date falls in the visit window .
Only unscheduled visits are slotted according to the table above and this slotting algorithm 
willbe applicable for both efficacy and safety domains.
After slotting of Un -scheduled visits, if there are multiple assessments at a planned time -
point, then the value closest to the target day for that window will be considered. If the
multiple assessments are equidistant from the target day, then mean of the assessments 
will be considered.
For any time post baseline and baseline ( if the definition of baseline is the latest pre -dose 
visit) all assessments are used irrespective of whether they fall into visit windows or not.
CON FIDENTIA L
200182
4112.4. Appendix 4: Study  Phases 
12.4.1. Study Phases 
Only Concomitant Medication will be reported by treatment phases and all other displays will be 
irrespective of the phases.
12.4.2. Study Phases for Concomitant Medication 
DefinitionTreatment Phase
Pre-Treatment On-Treatment *
Subject did not take study treatment ( e.g., screening failures) AND 
concomitant medication stop date > =date of ScreeningY
Concomitant medication start date < treatment start date AND (date of 
Screening < =concomitant medication stop date <treatment start date)Y
Concomitant medication start date < (treatment start date or screening 
Date) and the variable that defines the status of Concomitant medication 
end with respect to reference time -period is ("BEFORE”) Y
Concomitant medication start date < treatment start date AND the 
variable that defines the status of Concomitant medication end with 
respect to reference time -period is ("AFTER", “DURING”, 
“DURING/AFTER”, “ONGOING”)Y Y
Concomitant medication start date < treatment start date AND 
(treatment start date < concomitant medication stop date < =treatment 
stop date)Y Y
(Concomitant medication start date < treatment start date) AND 
(concomitant medication stop date > treatment stop date)Y Y
Treatment start date <= conco mitant medication start date Y
*On-Treatment phase includes both On -Treatment and Post -Treatment concomitant medications.
CON FIDENTIA L
200182
4212.5. Appendix 5: Data Display  Standards & Handling 
Conventions
12.5.1. Reporting Process
Software
The currently supported versions of SAS soft ware (Version 9.2 or higher) .
Reporting Area
HARP Server : us1salx00 259
HARP Compound : \ARPROD \GSK2881078 \mid200182 \
Analysis Datasets 
Analysis datasets will be created according to CDISC standards (SDTM IG Version 3.2 & AdaM IG 
Version 1.0.
For cre ation of A DaM datasets (ADCM/ADAE), the same version of dictionary datasets will be 
implemented as SDTM.
Generation of RTF Files
RTF files will be generated for each reporting effort.
12.5.2. Reporting Standards
General
The current GSK Integrated Data Standard s Library (IDSL) will be applied for reporting , unless 
otherwise stated (IDSL Standards Location: 
https://spope.gsk.com/sites/IDSLLibrary/SitePages/Home.aspx) :
4.03 to 4.23: General Principles
5.01 to 5.08: Principles Related to Data Listings
6.01 to 6.11: Principles Related to Summary Tables
7.01 to 7.13: Principles Related to Graphics
Formats
GSK IDSL Statistical Principles (5.03 & 6 .06.3) for decimal places (DP’s) will be adopted for reporting of 
data based on the raw dat a collected , unless otherwise stated.
Numeric data will be reported at the precision collected on the eCRF except for the parameters 
specified below.
Domain DP for Mean
Leg Press (Last Successful Lift 1 -Rep Max (kg)) 1 DP
Appendicular Lean Mass (kg) & Total Lean Mass (kg) 3 DP
PRO p arameters & SGRQ parameters 2 DP
Total Score for SPPB 1 DP
CAT 1 DP
Time for the Fastest Walk (sec) & Time Repeated Chair Stand 
Test (sec)3 DP
CON FIDENTIA L
200182
43Incremental Shuttle Walking test -Maximum Distance Walked 
(m)1 DP
CWR -Exercise Duration (sec) 1 DP
The reported precision from non eCRF sources will follow the IDSL statistical principles but may be
adjust ed to a clinically interpretable number of DP’s .
Planned and Actual Time
Reporting for tables, f igures and formal s tatistical analyses:
Planned time relative to dosing will be used in figures, summaries, statistical analyses and 
calculation of any derived parameters, unless otherwise stated.
Reporting for Data Listings: 
Planned and actual time relative to study drug dosing will be shown in listings (R efer to IDSL 
Statistical Principle 5.05.1).
Unscheduled or unplanned readings will be presented within the subject’s listings. 
Unscheduled Visits
Unscheduled visits will be assigned to a study visit using the assessment windows defined in 
Section 1 2.3. After slotting of Un -scheduled visits, if there are multiple assessments at a planned 
time-point, then the value closest to the target day for that window will be used. If its equidistant 
from the target day, t hen mean of the assessments will be used in summary and figures. Listing will 
show both the planned and un -scheduled assessments.
Data summaries will only report visits that are planned assessment time points for each parameter 
(according to the T&E table) which can include the unscheduled visits if slotted .
All unscheduled visits will be included in listings.
Unscheduled visits can be included in the derivation of any time post baseline visits and baseline if 
the definition of baseline is the latest pre -dose visi t(See Section 5.2 ).
Descriptive Summary Statistics
Continuous Data Refer to IDSL Statistical Principle 6.06.1
Categorical Data N, n, frequency, %
Graphical Displays
Refer to IDSL Statistical Principals 7.01 to 7.13.
CON FIDENTIA L
200182
4412.6. Appendix 6: Derived and Transformed Data
12.6.1. General
Multiple Measurements at One Analysis Time Point
Mean of the measureme nts (not in case of visit slotting) will be calculated and used in any derivation of 
summary statistics but if listed, all data will be presented .
If there are two values within a time window (as per Section 12.3.1 ) the value closest to the target day 
for that window will be used. If values are the same distance from the target, then the mean will be 
taken.
Participants having both High and Low values for Normal Ranges at any post -baseline visit for safety 
parameters will be counted in both the High and Low categories of “Any visit post -baseline” row of 
related summary tables. Thi s will also be applicable to relevant Potential Clinical Importance summary 
tables.
Study Day
Calculated as the number of days from First Dose Date :
Ref Date = Missing              → Study Day = Missing 
Ref Date < First Dose Date → Study Day = Ref Date –First Dose Date
Ref Data ≥ First Dose Date → Study Day = Ref Date –(First Dose Date )+ 1    
Note that Treatment Start Date is considered as Study D ay 1.
Post -baseline
Post-baseline refers to the combined time periods of On -treatment and Post -treatment.
Change from Baseline
=Post-baseline -Baseline
Ratio to Baseline
= exp(log (Post -baseline) -log (Baseline) )
Percent Change from Baseline
= 100*(Post -baseline –Baseline)/Baseline
Treatment compliance
=100 * (Total Amount Taken/ ( Treatment duration in days* 2) )
    Total Amount Taken = Total tablets dispensed –Total tablet sreturned –Total tablets lost.
12.6.2. Efficacy
Secondary Efficacy endpoin ts
Peak performance from incremental shuttle walking test
‘Maximum distance walk ed’collected from incremental shuttle walk testin CRF
Constant Work Rate (CWR) duration from endurance shuttle walking test
‘Exercise duration time (seconds) ’collected from endurance shuttle walk testin CRF
St George Respiratory Questionnaire (SGRQ) total score and domains
The total score and three component scores (Symptoms, Activity and Impacts )will be derived from St 
George Respiratory Questionnaire -COPD (SGRQ -c)raw scores based upon the score manual (ST 
CON FIDENTIA L
200182
45Secondary Efficacy endpoin ts
GEORGE’S RESPIRATORY QUESTIONNAIRE FOR COPD PATIENTS (SGRQ -C) Version No.1.3 
March 2016 )
First, sum the weights for all items with a positive response :
Symptoms component consists of all the questions (question 1 -7) in Part 1. The weights for Questions 
1-7 are summed. A single response is required to each item. If multiple responses are given to an item, 
the weights for the multiple positive responses should be averaged then added to the sum.
Activity component is calculated from the summed weights for the positive responses to items 
questions 9 and 12 in Part 2 of the questionnaire.
Impacts component is calculated from questions 8, 10, 11, 13, 14 in Part 2 of the questionnaire. The
weights for all positive res ponses to items in Questions 10, 11, 13 are summed together
with the responses to the single item that should have been checked (ticked) in Questions 8 and 14. In 
the case of multiple responses to either of these items, the average weight for the item shou ld be 
calculated.
Total score is calculated by summing the weight to all the positive responses in each component.
Then ,calculate the score :
The score for each component is calculated separately by dividing the summed weights by the 
maximum possible wei ght for that component and expressing the results as a percentage:
Sum of maximum possible weights for each component and Total:
Symptoms :    566.2      Impact:  1652.8
Activity :          982.9     Total:       3201.9
Last, converting SGRQ -c scores to be comparable to SGRQ:
The adjustment is:
Symptoms:   SGRQ score = (SGRQ -C x 0.99) + 0.94 units
Activity: SGRQ score = (SGRQ -C x 0.87) +7.01 units
Impacts: SGRQ score = (SGRQ -C x 0.88) +2.18 units
Total: SGRQ score = (SGRQ -C x 0.90) + 3.10 units
Handling of m issing items
ATotal score can be calculated in the presence of missing data, but only if the domains meet their 
‘missing items’ rules (see below). If one domain exceeds its permitted number of missed items, then a 
total score cannot be calculated.
Sympto ms:The Symptoms component will tolerate a maximum of 1 missed item. The weight for the 
missed item is subtracted from the total possible weight for the Symptoms component (566.2) and from 
the Total weight (3201.9) and then calculate the score.
Activity :The Activity component will tolerate a maximum of 3 missed items. The weight for the missed 
item (s)is subtracted from the total possible weight for the Activity component (982.9) and from the 
Total weight (3201.9) and then calculate the score.
Impacts :The Impacts component will tolerate a maximum of 5 missed items. The weight for the missed 
item (s)is subtracted from the total possible weight for the Impacts component (1652.8) and from the 
Total weight (3201.9 )and then calculate the score.
Responder is defined as ‘Yes’ when the total score at a post -baseline visit decreases by 4 or more from 
baseline total score, otherwise, non -responder.
CON FIDENTIA L
200182
46Secondary Efficacy endpoin ts
Total Short Physical Performance Battery (SPPB) score and times for chair rise and 4 m gait 
speed
Total SPPB score, ‘ Time for five stands done successfully ’collected for chair and ‘time for fastest walk 
for 4 m gait test’ collected from CRF will be used ,respectively
SPPB at baseline will be categorized as below:
      SPPB 10 -12 points fit patient, normal 
      SPPB 8 -9 points pre -frail patient 
      SPPB ≤ 7 points frail patient
COPD Assessment Test (CAT)
Total score of 8 questions will be used
Responder is defined as ‘Yes’ when the total score at a post -baseline visit decreases by 2 or more from 
baseline total score, otherwise, non -responder.
If one or more of the 8 questions are missing the total score and the responder will be missing.
PROactive endpoints (individual components (Difficulty and Amount) and total score)
The PROactive instrument ( IMI PROACTIVE IN COPD DAILY AND CLINICAL INSTRUMENTS D-
PPAC and C -PPAC 2016 (Use D -PPAC for the calculation of scores)) combine sa PRO questionnaire 
and an activity monitor to measure physical activity in COPD patients . Itis 9-item daily assessments
covering 2 different domains (amount and difficulty) desi gned for electronic administration. The ‘amount’ 
domain is covered by 2 items (questions - amount of walking outside and chores outside) and by 2 
activity monitor outputs (vector magnitude units per minute (VMU/min) and steps/day). The ‘difficulty’ 
domain is covered by 5 items (questions). 
The scores for activity monitor outputs ,step counts and VMU’s is assigned based on the 5 level
categories they are falling in (see the table below).
Scores VMU/min Steps/day
Calculat ion of daily score for each domain (amount, difficulty) and total score :
First, domains are scored by simple adding items, which, the values are 0-17 for ‘amo unt’ and 0-20 for 
‘difficulty’. T he raw scores are then scaled to a score ranging from 0 to 100, based on Table 1 in the 
guidance (see Reference)
The ‘total score’ is obtained calculating the average between two domains. This score has the same 
scale of two individual domains, from 0 to 100.
PROactive scores for a day cannot be calculated if the subjects missed any of the 9 items in any day.
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected 
by third party copyright laws and therefore have been excluded.
CON FIDENTIA L
200182
47Secondary Efficacy endpoin ts
Calculat ion of the w eekly score for each domain (amount, difficulty) and to tal score :
The average of the daily scores during a 7-day period will be the weekly score separately for each 
domain ( amount, difficulty )and total score.
Score eligibility :
Adequate physical activity data are considered for days where more than eight hours of wearing time is 
available. The activi ty monitor measurement days used should be concurrent with the questionnaire.
At least four days with ≥ 8 hours of wearing time of activity monitor data are required for the 
measurements to be valid for a weekly average. These fourdays should be in the same week (7 days 
from the first day of assessments) , do not need to be consecutive, and could cover weekdays or 
weekend days without distinction.
Physical Activity Measures 
At least four days with ≥ 8 hours of wearing time of activity monitor data are required for the 
measurements to be valid for a weekly average. These four days should be i n the same week (7 days 
from the first day of assessments), do not need to be consecutive, and could cover weekdays or 
weekend days without distinction. Then calculate the average by dividing total with number of days.
The physical activity measures weekly average steps, weekly average vector magnitude unit/wear time 
and weekly average moderate/vigorous activity duration have the same derivation.
The number of subjects included: The count of subject in each visit who has wear time more than 8 
hours for at l east 4 days in a week. 
Average number of days included per subject: This the average number of days with wear duration 
more than 8 hours for at least 4 days in each visit .
Average number of minutes included per subject: This the average wear duration in m inutes for those 
subjects with more than 8 hours of wear duration for at least 4 days in a week for each visit.
12.6.3. Safety
Extent of Exposure
Number of days of exposure to study drug will be calculated based on the formula:  
Duration of Exposure in Days = Treatment Stop Date –(Treatment Start Date) + 1
The number of days exposure therefore does not take into account dose interruptions.
Participants who were randomized but did not report a treatment start date will be categorised as 
having zero days of exp osure. 
Actual amount taken (number of tablets) = Total tablets dispensed –Total tablet sreturned –Total 
tablets lost.
Females will take 1 mg everyday (2*0.5mg tables) and males will take 2 mg (2*1mg). So,the a ctual 
dose (mg) taken will be the same as a ctual amount taken for males and for females it will be actual 
amount taken divided by 2 .
The cumulative actual dose (mg) will be the sum of the actual dose staken.
Adverse Events
Onset Time Since 
1st Dose (Days)If Treatment Start Datetime ≤ AE Onset D atetime , then AE Onset Datetime -
Treatment Start Datetime +1
If time part is missing in any of the Datetime, then use the Treatment Start date and AE 
CON FIDENTIA L
200182
48Extent of Exposure
Onset date in calculation and m issing otherwise.
Duration (Days) AE Resolution Datetime –AE Onset Dat etime + 1
If time part is missing in any of the Datetime, then use the AE Resolution date and AE 
Onset date in calculation and m issing otherwise.
Drug -related Ifthe question ‘is there a reasonable possibility that AE may have been caused by the 
Study Tre atment’ is marked ‘YES’ on CRF or is missing . 
MRI 
Body Surface Area (BSA) (m 2) =0.007184 * Weight (kg) 0.425* Height (cm) 0.725
Left Ventricular End Systolic Volume Index (LVESVi)=
Left Ventricular End Diastolic Volume Index (LVEDVi)=
Adverse Events
Adverse Events of Special Interest (AESI))
The following table presents the AESI. AESI which are not SMQs are made up of a selection of preferred 
terms (PTs) defined by GSK. The complete list of AESI , including the PTs which con tribute to each of the 
AESI will be provided by Safety and Medical Governance using the MedDRA version current at the time of 
reporting. 
AESI Group of terms (MedDRA SMQ, HLT or individual PTs)
Drug related hepatic 
disordersDrug related hepatic disor ders –comprehensive search (SMQ)
Reproductive organ 
effects, maleProstatic neoplasms and hypertrophy HLT plus selected preferred terms:
Prostatic specific antigen abnormal
Prostatic specific antigen increased
Reproductive organ 
effects, femaleFemale g onadal function disorders HLT (includes PT of Hirsutism and Virilism)
Virilism in females Hirsutism PT, Virilism PT, Acnes HLT, Dysphonia PT
Dyslipidaemia Dyslipidaemia SMQ
Bone effects Osteoporosis/osteopenia (SMQ),
Plus, selected Fracture PTs (57 term s)
MedDRA PT PT Code
Ankle fracture 10002544
Bone decalcification 10070817
Bone disorder 10005956
Bone fragmentation 10064211
Clavicle fracture 10009245
Comminuted fracture 10052614
Complicated fracture 10010149
Compression fracture 10010214
CON FIDENTIA L
200182
49Epiph yseal fracture 10053962
Facial bones fracture 10016042
Fibula fracture 10016667
Foot fracture 10016970
Fracture delayed union 10017081
Fracture displacement 10053206
Fracture reduction 10057609
Fractured coccyx 10049164
Fractured skull depressed 10017310
Greenstick fracture 10018720
Hand fracture 10019114
Humerus fracture 10020462
Impacted fracture 10066386
Internal fixation of spine 10069749
Jaw fracture 10023149
Lower limb fracture 10061599
Open fracture 10030527
Osteocalcin decreased 10050940
Osteonecrosis 10031264
Osteonecrosis of jaw 10064658
Patella fracture 10034122
Scapula fracture 10039579
Skeletal injury 10061363
Skull fracture 10061365
Skull fractured base 10040960
Sternal fracture 10042015
Stress fracture 10042212
Tibia fracture 10043827
Torus fracture 10066094
Traumatic fracture 10049514
Ulna fracture 10045375
Upper limb fracture 10061394
Vertebral wedging 10065317
Atypical fracture 10072395
Avulsion fracture 10066184
Chance fracture 10073162
Limb fracture 1007 4551
Osteochondral fracture 10073853
Periprosthetic fracture 10069135
Spinal fusion fracture 10074807
Fracture malunion 10017085
Fracture nonunion 10017088
Craniofacial fracture 10077603
Spinal flattening 10077756
Bone metabolism biochemical marker
increased10078949
Subchondral insufficiency fracture 10079864
CON FIDENTIA L
200182
50Maisonneuve fracture 10081343
Degenerative bone disease 10081730
Internal fixation of fracture 10022576
Cardiovascular effects See the table below.
Hypersensitivity Hypersensitivity ( SMQ) narrow, Angioedema (SMQ) narrow, Anaphylactic reaction 
(SMQ) narrow
Hostility/aggression Hostility/aggression (SMQ)
Sexual desire 
disordersSexual desire disorders HLT
Embolic and 
thrombotic eventsEmbolic and thrombotic events (SMQ)
Cardiovascul ar effects AESI
AESI AESI Subgroup Sub-SMQ Scope
Cardiovascular 
effectsCardiac arrhythmia Arrhythmia related investigations, 
signs and symptoms (SMQ)Broad
Bradyarrhythmia terms, nonspecific 
(SMQ)Broad
Conduction defects (SMQ) Broad
Disorders of sinus node function 
(SMQ)Broad
Cardiac arrhythmia terms, 
nonspecific (SMQ)Broad
Supraventricular tachyarrhythmias 
(SMQ)Broad
Tachyarrhythmia terms, nonspecific 
(SMQ)Broad
Ventricular tachyarrhythmias (SMQ) Broad
Cardiac failure (SMQ) Broad
Ischaemic heart 
disease (SMQ)Broad
Hypertension (SMQ) Broad
Central nervous 
system haemorrhages 
and cerebrovascular 
conditions (SMQ)Broad
Cardiomyopathy 
(SMQ)Narrow
ECG Parameters
General
The summary should be based on average va lue of triplicate ECG readings obtained over a brief 
recording period (missing readings will not be counted) .
Eligibility Criteria 
The QT values at screening will be using for the eligibility checking of subjects .
CON FIDENTIA L
200182
51ECG Parameters
Stopping Criteria
A subject who meet either of the bulleted criteria below will be withdrawn from the study:
QT interval corrected for heart rate by Bazett's formula (QTcB) or QT interval corrected for heart 
rate by Fridericia’s formula (QTcF) >450 msec 
QT interval corrected for heart rate ( QTc) >480 msec in participants with Bundle Branch Block 
based on a single ECG. 
Laboratory Parameters
General
All clinical laboratory tests will be based on central laboratory assessments only. If a laboratory value 
which is expected to have a numeric value for summary purposes, has a non -detectable level reported 
in the database, where the numeric value is missing, but typically a character value starting with ‘<x’ or 
‘>x’ (or indicated as less than x or greater than x in the comment field) is present, thenumber of 
significant digits in the observed values will be used to determine how much to add or subtract in order 
to impute the corresponding numeric value. 
oExample 1: 2 Significant Digits =  ‘< x ‘ becomes x –0.01
oExample 2: 1 Significant Digit s  =  ‘> x’ becomes x + 0.1
oExample 3: 0 Significant Digits = ‘< x’ becomes x –1    
Laboratory Toxicity Grade
Toxicities will be based on FDA guidance ‘Common Terminology Criteria for adverse events v4.03 
(CTCAE) defined by NCI -CTEP (National Cancer Inst itute –Cancer Therapy Evaluation Program).
When summarising toxicity grades for such parameters, they will be categorised as to whether they are 
above or below the normal range.
Parameter Below Normal Range Above Normal Range
Fasted glucose Hypoglycaemi a Hyperglycaemia
Sodium Hyponatremia Hypernatremia
Potassium Hypokalemia Hyperkalemia
Calcium Hypocalcemia Hypercalcemia
Hepatitis Status
Hepatitis B and C will be determined using antibody (IgM or IgG) at the screening or within 3 months 
prior to f irst dose of study treatment . If there is evidence of Hepatitis C antibodies a tthescreening visit, 
then Hepatitis C viral RNA PCR is required to exclude active infection . This sample is not needed if 
Hepatitis C screening is negative
Antibody (IgM or IgG ) status with ‘BORDERLINE’ or ‘REACTIVE’ will be considered Positive
A subject will be considered positive for hepatitis B virus (HBV) if they have a positive surface antigen 
(HBsAg) during screening. Subjects positive for HBV are not allowed to enter the study
COPD Exacerbation Event Count
The total number of exacerbation events is determined by summing the number of times there is a non -
missing “Date of Onset” on the exacerbation CRF page” for a subject
The number of exacerbating patients refers to the count of the unique patient in the COPD 
Exacerbation CRF data. In other words, it is the total number of patients who experience one or more 
exacerbations defied in the first bullet .
CON FIDENTIA L
200182
5212.7. Appendix 7: Reporting Standards for Missing Data
12.7.1. Premature Withdrawals
Element Reporting Detail
General Subject study completion (i.e. as specified in the protocol) was defined as subjects who 
completed all visits of the study including the follow -up visit.
Withdrawn subjects may be replaced in the study .
All available data from participants who were withdrawn from the study will be listed 
and all available planned data will be included in summary tables and figures, unless 
otherwise specified.
Withdrawal visits will be assigned to a planned visit or an unscheduled visit andwillbe 
slotted as per Appendix 3 :Assessment Windows .
12.7.2. Handling of Missing Data
Element Reporting Detail
General Missing data occurs when any requested data is not provided, leading to blank fields on 
the coll ection instrument:
oThese data will be indicated by the use of a “blank” in subject listing displays. 
Unless all data for a specific visit are missing in which case the data is excluded 
from the table. 
oAnswers such as “Not applicable” and “Not evaluable” a re not considered to be 
missing data and should be displayed as such.
Outliers Any participants excluded from the summaries and/or statistical analyses will be 
documented along with the reason for exclusion in the clinical study report.
12.7.2.1. Handling of Missi ngand Partial Dates
Element Reporting Detail
General Partial dates will be displayed as captured in subject listing displays.
Adverse 
EventsThe eCRF allows for the possibility of partial dates (i.e., only month and year) to be 
recorded for AE start and end dates; that is, the day of the month may be missing. In 
such a case, the following conventions will be applied for calculating the time to onset 
and the duration of the event:
oMissing Start Day:First of the month will be used unless this is before th e start 
date of study treatment ; in this case the study treatment start date will be used .
oMissing Stop Day:Last day of the month will be used, unless this is after the stop 
date of study treatment ; in this case the study treatment stop date will be used.
Completely missing start or end dates will remain missing, with no imputation applied. 
Consequently, time to onset and duration of such events will be missing.
Concomitant 
Medications/
Medical 
HistoryPartial dates for any concomitant medications recorded in the CRF will be imputed 
using the following convention:
oIf the partial date is a start date, a '01' will be used for the day and 'Jan' will be 
used for the month
oIf the partial date is a stop date, a '28/29/30/31' will be used for the day (dependent 
onthe month and year) and 'Dec' will be used for the month.
The recorded partial date will be displayed in listings.
CON FIDENTIA L
200182
5312.8. Appendix 8: Values of Potential Clinical Importance
12.8.1. Laboratory  Values
Haematology
Laboratory Parameter Units Category Clinical Concern Ra nge
Low Flag (< 
x)High Flag (>x)
Hematocrit Ratio of 
1Male 0.54
Female 0.54
∆from BL
(Female & Male)0.075
Haemoglobin g/LMale 180
Female 180
∆from BL 
(Female & Male)25
Lymphocytes x109/ L 0.8
Neutrophil Count x109/ L 1.5
Platelet Count x109/ L 100 550
White Blood Count (WBC) x109/ L 3 20
Clinical Ch emistry
Laboratory Parameter Units Category Clinical Concern Range
Low Flag (< x) High Flag (>x)
Albumin g/L 30
Calcium mmol/L 2 2.75
Creatinine µmol/L ∆from BL 44.2
Glucose mmol/L 3 9
Phosphorus mmol/L 0.8 1.6
Potassium mmol/L 3 5.5
Sodium mmol/L 130 150
Total CO2 (Bicarbonate) mmol/L 18 32
Liver Function
Test Analyte Units Category Clinical Concern Range
ALT/SGPT U/L High >=3xULN
AST/SGOT U/L High >=2xULN
Alkaline phosphatase U/L High >=2xULN
T Bilirubin µmol/L High >=1.5ULN
T. Bilirubin + ALTµmol/L
High>=1.5ULN T. Bilirubin
+
U/L >=3xULN ALT
CON FIDENTIA L
200182
5412.8.2. ECG
ECG Parameter Units Clinical Concern Range
Lower Upper
Absolute
Absolute QTc Interval msec N/A > 500
Uncorrected QT msec N/A > 600
Change from Baseline
Increas e from Baseline QTc msec N/A > 60
12.8.3. Vital Signs
Vital Sign Parameter
(Absolute)Units Clinical Concern Range
Lower Upper
Systolic Blood Pressure mmHg <85 >160
Diastolic Blood Pressure mmHg <45 >100
Pulse Rate Beats/min <40 >110
Respiratory Rate breat hs/min N/A >20
Temperature (skin) °C N/A >38
CON FIDENTIA L
200182
5512.9. Appendix 9: Model Checking and Diagnostics for Statistical 
Analyses
Analysis       Mixed Model Repeated Measure ( MMRM )
Distributional assumptions underlying the model used for analysis will be examined by
obtaining a normal probability plot of the residuals and a plot of the residuals versus the fitted 
values (i.e. checking the normality assumption and constant variance assumption of the model 
respectively) to gain confidence that the model assumptions are reasonable.
Analysis       Bayesian Analysis
Non-informative prior should be plotted to make sure it is truly non -informative .
Adequate values for the number of MCMC samples / thinning / number of burn -in
samples should be chosen to ensure that the rati o Monte Carlo Standard Errors (MCSE) and 
standard deviation of the posterior distribution for all the parameters in the model as small as 
possible, typically close to 0.01.
In addition, if possible, the number of tuning units and maximum number of tuning i terations 
may be increased to find a better proposal distribution for the model parameters, which in turn 
may reduce the MCSE/SD ratio.
The Geweke diagnostic test checks whether the mean estimates have converged by 
comparing means from the early and latter part of the Markov chain using a z score t -test. 
Large absolute values of the z -score statistic indicate rejection of the null hypothesis of no 
difference between the mean estimates obtained from the early and latter parts of the chain.
The convergence di agnostics for all parameters in the Bayesian analysis will be visually 
checked by the trace plots.
If the trace plots show apparent trend or the autocorrelation plots show significant positive or 
negative autocorrelation, number of iterations will be incre ased or reparameterization might be 
explored.
Analysis Analysis of covariance (ANCOVA)
Distributional assumptions underlying the model used for analysis will be examined by 
obtaining a normal probability plot of the residuals and a plot of the residuals versus the fitted 
values (i.e. checking the normality assumption and constant variance assumption of the model 
respectively) to gain confidence that the model assumptions are reasonable.
CON FIDENTIA L
200182
5612.10. Appendix 10: Abbreviations & Trade Marks
12.10.1. Abbrev iations
Abbreviatio n Description
1-RM 1 repetition maximum
AP Analysis Population
A&R Analysis and Reporting 
ADaM Analysis Data Model
AE Adverse Event
AIC Akaike's Information Criteria
BDRM Blinded data review meeting
BP Blood Pressure
BS Biostatistics
CAT COPD As sessment Test
CDISC Clinical Data Interchange Standards Consortium
CI Confidence Interval
COPD Chronic Obstructive Pulmonary Disease
CPMS Clinical Pharmacology Modelling & Simulation
CRF Case report form
CS Clinical Statistics
CSR Clinical Study Rep ort
CTR Clinical Trial Register
CV Cardiovascular
CVA Cerebrovascular event stroke 
CWR Constant Work Rate
DAP Data Analysis Plan
DBF Database Freeze
DBR Database Release
DM Data management
DOB Date of Birth
DP Decimal Places
DVT Deep vein throm bosis 
DXA Dual-energy X -ray Absorptiometry
ECG Electrocardiogram
eCRF Electronic Case Record Form
EMA European Medicines Agency
FDA Food and Drug Administration
FDAAA Food and Drug Administration Clinical Results Disclosure Requirements
FSH Follicl e-stimulating hormone
GSK GlaxoSmithKline
HR Heart rate
IA Interim Analysis
ICH International Conference on Harmonization
IDSL Integrated Data Standards Library
IMMS International Modules Management System
CON FIDENTIA L
200182
57Abbreviatio n Description
IP Investigational Product
LH Luteinizing hormone
LVEF Left ventricular ejection fraction
MMRM Mixed Model Repeated Measures
MRI Magnetic Resonance Imaging
PCI Potential Clinical Importance 
PD Pharmacodynamic
PDMP Protocol Deviation Management Plan
PE Pulmonary embolism 
PGIC Patient Glob al Impression of Change
PGRS Patient Global Rating of Severity
PSA Prostate specific antigen
PK Pharmacokinetic
PP Per Protocol
QC Quality Control
QTcB Bazett’s QT Interval Corrected for Heart Rate
QTcF Frederica’s QT Interval Corrected for Heart Ra te
RAMOS Randomization & Medication Ordering System 
RAP Reporting & Analysis Plan
SAC Statistical Analysis Complete
SARM Selective Androgen Receptor Modulator
SD Standard deviation
SDSP Study Data Standardization Plan
SDTM Study Data Tabulation Mod el
SE Standard error
SGRQ St George Respiratory Questionnaire
SGRQ -c St George Respiratory Questionnaire -COPD
SMG Safety and Medical Governance
SnIP Sniff Nasal Inspiratory Pressure
SOP Standard Operation Procedure
SPPB Short Physical Performance Ba ttery
SRT Safety Review Team
SHBG Sex hormone -binding globulin
TA Therapeutic Area
TFL Tables, Figures & Listings 
TIA Transient ischemic attack 
FEV1 Forced Expiratory Volume in 1 second
SnIP Sniff Nasal Inspiratory Pressure
CON FIDENTIA L
200182
5812.10.2. Trademarks
Trademarks of the GlaxoSmithKline 
Group of CompaniesTrademarks not owned by the 
GlaxoSmithKline Group of Companies
None None
CON FIDENTIA L
200182
5912.11. Appendix 11: List of Data Display s
12.11.1. Data Display  Numbering
The following numbering will be applied for RAP generated displays :
Section Tables Figures
Study Population 1.1 to 1. 13
Efficacy 2.1 to 2.47 2.1 to 2.9
Safety 3.1to 3.36 3.1 to 3.4
PK 4.1
Section Listings
ICH Listings 1 to 34
Other Listings 35to 89
12.11.2. Mock Example Shell Referencing
Non IDSL specifications will be referenc ed as indicated andif required example mock -up displays 
provided inAppendix 12 : Example Mock Shells for Data Displays .
Section Figure Table Listing
Study Population POP_F n POP_T n POP_L n
Efficacy EFF_F n EFF_T n EFF_Ln
Safety SAFE_F n SAFE_T n SAFE_L n
NOTES: 
Non-Standard display s are indicated in the ‘IDSL / Example Shell’ or ‘Programming Notes’ column as ‘[Non -
Standard] + Reference.’
12.11.3. Deliverable s
Delivery Description
SAC Final Statistical Analysis Complete
CONFIDENTIA L
200182
6012.11.4. Study Population Tables
Study Population Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Subject Disposition
1.1.All 
ParticipantsES1 Summary of Subject Disposition for the Subject Conclusion 
RecordICH E3 , FDAAA, EudraCT SAC 
1.2.All 
ParticipantsSD1 Summary of Treatment Status and Reasons for Discontinuation 
of Study TreatmentICH E3 SAC 
1.3. Screened ES6 Summary of Screening Status and Reasons for Screen FailureJournal Requirements
SAC 
1.4. Enrolled NS1 Summary of Number of Participant by Country and Site ID EudraCT/ Clinical Operations SAC
Protocol Deviation
1.5.All 
ParticipantsDV1 Summary of Important Protocol Deviations ICH E3 SAC
Population Analysed
1.6. Screened SP1 Summary of Study Populations IDSLHeadline 
Results & SAC 
1.7.All 
ParticipantsSP2Summary of Exclusions from the Per Protocol Population IDSL SAC
Demographic and Baseline Characteristics
  1.8.All 
ParticipantsDM1 Summary of Demographic CharacteristicsICH E3, FD AAA, EudraCT
Footnote: Age is imputed when full date 
of birth is not provided.Headline 
Results & SAC
CONFIDENTIA L
200182
61Study Population Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
1.9. Enrolled DM11 Summary of Age RangesEudraCT
Footnote: Age is imputed when full date 
of birth is not provided.SAC
1.10.All 
ParticipantsDM5 Summar y of Race and Racial Combinations ICH E3, FDA, FDAAA, EudraCT SAC
Prior and Concomitant Medications
1.11.All 
ParticipantsMH4 Summary of Medical Conditions ICH E3 SAC 
1.12.All 
ParticipantsCM1 Summary of Concomitant MedicationsICH E3
Note: On-Treat ment phase includes 
both On -Treatment and Post -Treatment 
concomitant medications.SAC 
Exposure
1.13. Safety EX1 Summary of Extent of Exposure to Investigational Product ICH E3 SAC
CONFIDENTIA L
200182
6212.11.5. Efficacy  Tables
Efficacy: Tables
No. PopulationIDSL / 
Exam ple ShellTitle Programming NotesDeliverable 
[Priority]
Primary Efficacy
2.1. Analysis EFF_T1Analysis of Percen t Change from Baseline in Leg Press Strength
(%)by Visit -Repeated Measure Mixed ModelHeadline 
Results & SAC
2.2. Per ProtocolEFF_T1 Analysis of Percent Change from Baseline in Leg Press Strength
(%)by Visit -Repeated Measure Mixed ModelSAC 
2.3. AnalysisEFF_T1 Analysis of Change from Baseline in L eg Press Strength (kg) by 
Visit -Repeated Measure Mixed ModelSAC 
2.4. Per ProtocolEFF_T1 Analysis of Chan ge from Baseline in Leg Press Strength (kg)by 
Visit-Repeated Measure Mixed ModelSAC 
2.5. AnalysisEFF_T 2 Bayesian Analysis of Percentage Change from Baseline in Leg 
Press Strength (%)by VisitHeadline 
Results & SAC
2.6. Analysis EFF_T 3 Descriptive Summ ary of Change and Percent Change from 
Baseline in Leg Press Strength by VisitSummarize the data for change from 
baseline, percentage change from 
baseline and ratio to baseline along 
with the data at each visit for 
parameters Last Successful Lift 1 -Rep 
Max (kg), Number of Successful Lifts 
and Starting Lift Weight (kg).Headline 
Results & SAC
CONFIDENTIA L
200182
632.7. Per ProtocolEFF_T 3 Descriptive Summary of Change and Percent Change from 
Baseline in Leg Press Strength by VisitSummarize the data for change from 
baseline, perc entage change from 
baseline and ratio to baseline along 
with the data at each visit for 
parameters Last Successful Lift 1 -Rep 
Max (kg), Number of Successful Lifts 
and Starting Lift Weight (kg).SAC
2.8. AnalysisEFF_T1Analysis of Percent Change from Baseline in Leg Press Strength
(%)by Visit -Repeated Measure Mixed Model with Exploratory 
CovariateAdd the exploratory covariates 
predicted FEV1 and BMI at baseline in 
the same model for T able 2.1.
Update the shell footnote by adding the 
exploratory covariate s SAC
Secondary Efficacy
2.9. Analysis EFF_T1Analysis of Change from Baseline in Appendicular (kg), and 
Total Lean Mass (kg)as Assessed by Dual -energy X -ray 
Absorptiometry by Visit -Repeated Measure Mixed ModelSimilar shell as EFF_T1, add a by line 
forParameter under the Sex 
p-value is not requiredHeadline 
Results & SAC
2.10. AnalysisEFF_T1 Analysis of Percent Change from Baseline in Appendicular (%), 
and Total Lean Mass (%)as Assessed by Dual -energy X -ray 
Absorptiometry by Visit -Repeated Measure Mix ed ModelSimilar shell as EFF_T1, add a by line 
for Parameter under the Sex
p-value is not requiredSAC 
2.11. Analysis EFF_T 3Descriptive Summary of Change and Percent Change from 
Baseline in Appendicular and Total Lean Mass as Assessed by 
Dual-energy X -ray Absorptiometry by VisitSummarize the data for change from 
baseline, percentage change from 
baseline and ratio to baseline along 
with the data at each visitHeadline 
Results & SAC
2.12. AnalysisEFF_T1 Analysis of Change from Baseline in PROactive Total Score , 
Difficulty and Amount Scores by Visit -Repeated Measure Mixed 
ModelSimilar shell as EFF_T1, add a by line 
for Parameter under the Sex
p-value is not requiredHeadline 
Results & SAC
CONFIDENTIA L
200182
642.13. Per ProtocolEFF_T1 Analysis of Change from Baseline in PROactive To tal Score , 
Difficulty and Amount Scores by Visit -Repeated Measure Mixed 
ModelSimilar shell as EFF_T1, add a by line 
for Parameter under the Sex
p-value is not requiredSAC
2.14.Analysis EFF_T 2 Bayesian Analysis of Change from Baseline in PROactive Total 
Scoreby VisitHeadline 
Results & SAC
2.15. Analysis EFF_T 3Descriptive Summary of Change from Baseline in PROactive 
Total Score, Difficulty and Amount Scores by VisitSummarize the data for change from 
baseline and ratio to baseline along 
with the data at each visitHeadline 
Results & SAC
2.16.Per ProtocolEFF_T 3Descriptive Summary of Change from Baseline in PROactive 
Total Score, Difficulty and Amounts Scores by VisitSummarize the data for change from 
baseline and ratio to baseline along 
with the data at each visitSAC
2.17.Analysis EFF_T1 Analysis of Change from Baseline in COPD Assessment Test 
(CAT) score by Visit -Repeated Measure Mixed ModelSimilar shell as EFF_T1, p -value is not 
requiredSAC 
2.18.Analysis EFF_T 6 Responder Analysis of COPD Assessment Test 
(CAT) SAC
2.19.Analysis EFF_T 3 Descriptive Summary of Change from Baseline in COPD 
Assessment Test (CAT) score by VisitSummarize the data for change from 
baseline and ratio to baseline along 
with the data at each visitSAC
2.20. Analysis EFF_T 7Analysis of Chan ge from Baseline in St George Respiratory 
Questionnaire (SGRQ) Total Score and Domains Score at Day 
90 -ANCOVA ModelHeadline 
Results & SAC
2.21. Per Protocol EFF_T 7Analysis of Change from Baseline in St George Respiratory 
Questionnaire (SGRQ) Total Scor e and Domains Score at Day 
90 –ANCOVA ModelSAC
2.22.Analysis EFF_T 6 Responder Analysis of St George Respiratory Questionnaire 
(SGRQ) SAC
2.23.Analysis EFF_T2 Bayesian Analysis of Change from Baseline in St George 
Respiratory Questionnaire (SGRQ) Total Score at Day 90Same as EFF_T2, remove the visit 
columnHeadline 
Results & SAC
CONFIDENTIA L
200182
652.24. Analysis EFF_T 3Descriptive Summary of Change from Baseline in St George 
Respiratory Questionnaire (SGRQ) Total Score and Domains 
Scores by VisitSummarize the data for change f rom 
baseline and ratio to baseline along 
with the data at each visitHeadline 
Results & SAC
2.25. Per Protocol EFF_T 3Descriptive Summary of Change from Baseline in St George 
Respiratory Questionnaire (SGRQ) Total Score and Domains 
Scores by VisitSummarize the data for change from 
baseline and ratio to baseline along 
with the data at each visitSAC
2.26. AnalysisEFF_T1Analysis of Change from baseline in total Short Physical 
Performance Battery (SPPB) score and times for chair rise (sec)
and 4 m gait speed (sec) by Visit -Repeated Measure Mixed 
ModelSimilar shell as EFF_T1, add a by line 
for Parameter under the Sex
p-value is not requiredHeadline 
Results & SAC
2.27. Per ProtocolEFF_T1Analysis of Change from baseline in total Short Physical 
Performance Batt ery (SPPB) score and times for chair rise (sec)
and 4 m gait speed (sec) by Visit -Repeated Measure Mixed 
ModelSimilar shell as EFF_T1, add a by line 
for Parameter under the Sex
p-value is not requiredSAC 
2.28. AnalysisEFF_T 2 Bayesian Analysis of Change f rom Baseline in Times for chair 
rise(sec) by VisitHeadline 
Results & SAC
2.29. Analysis EFF_T 3Descriptive Summary of Change from baseline in total Short 
Physical Performance Battery (SPPB) score and times for chair 
rise and 4 m gait speed by Visit Summar ize the data for change from 
baseline and ratio to baseline along 
with the data at each visitHeadline 
Results & SAC
2.30. Per Protocol EFF_T 3Descriptive Summary of Change from baseline in total Short 
Physical Performance Battery (SPPB) score and times for c hair 
rise and 4 m gait speed by Visit Summarize the data for change from 
baseline and ratio to baseline along 
with the data at each visitSAC
2.31.Analysis EFF_T 7 Analysis of Change from Baseline in Constant Work Rate 
(CWR) Duration (sec) from Endurance Shut tle Walking Test at 
Day 90 –ANCOVA modelSimilar shell as EFF_T7 , remove the 
column ‘Parameter’Headline 
Results & SAC
2.32.Per Protocol EFF_T7 Analysis of Change from Baseline in Constant Work Rate 
(CWR) Duration (sec) from Endurance Shuttle Walking Test at
Day 90 –ANCOVA modelSimilar shell as EFF_T7 , remove the 
column ‘Parameter’SAC
CONFIDENTIA L
200182
662.33.Analysis EFF_T7Analysis of Percent Change from Baseline in Constant Work 
Rate (CWR) Duration (%) from Endurance Shuttle Walking Test 
at Day 90 –ANCOVA modelSimilar shell as EFF_T7, remove the 
column ‘Parameter’
Update footnote [ 1] as “ [1] Lsmeans of 
percent change from baseline for each 
treatment group as well as the 
difference of lsmeans of percent 
change from baseline is estimated from 
ANCOVA model with baselin e score as 
the covariate adjusting for the 
treatment. In case of violation of the 
assumptions, the same model is fitted 
with log of ratio to baseline and 
replacing the covariate baseline with 
log baseline. ”SAC
2.34.Analysis EFF_T2 Bayesian Analysis of Ch ange from Baseline in Constant Work 
Rate (CWR) Duration (sec) from Endurance Shuttle Walking 
Test at Day 90Same as EFF_T2, remove the visit 
columnHeadline 
Results & SAC
2.35.Analysis EFF_T 3Descriptive Summary of Change and Percent Change from 
Baseline in C onstant Work Rate (CWR) Duration from 
Endurance Shuttle Walking Test by VisitSummarize the data for change from 
baseline, percentage change from 
baseline and ratio to baseline along 
with the data at each visitHeadline 
Results & SAC
2.36.Per Protocol EFF_T 3Descriptive Summary of Change and Percent Change from 
Baseline in Constant Work Rate (CWR) Duration from 
Endurance Shuttle Walking Test by VisitSummarize the data for change from 
baseline, percentage change from 
baseline and ratio to baseline along 
with the data at each visitSAC
2.37.Analysis EFF_T7 Analysis of Change from Baseline in Peak Performance from 
Incremental Shuttle Walking Test at Day 90 –ANCOVA ModelSimilar shell as EFF_T7, remove the 
column ‘Parameter’SAC 
CONFIDENTIA L
200182
672.38.Analysis EFF_T7
Analysis of Percent Change from Baseline in Peak Performance 
from Incremental Shuttle Walking Test (%)at Day 90 –
ANCOVA ModelSimilar shell as EFF_T7, remove the 
column ‘Parameter’
Update footnote [ 1] as “ [1] Lsmeans of 
percent change from baseline for each 
treatme nt group as well as the 
difference of lsmeans of percent 
change from baseline is estimated from 
ANCOVA model with baseline score as 
the covariate adjusting for the 
treatment. In case of violation of the 
assumptions, the same model is fitted 
with log of rat io to baseline and 
replacing the covariate baseline with 
log baseline. ”SAC
2.39.Analysis EFF_T 3Descriptive Summary of Change and Percent Change from 
Baseline in Peak Performance from Incremental Shuttle Walking 
Test by VisitSummarize the data fo r change from 
baseline, percentage change from 
baseline and ratio to baseline along 
with the data at each visit .
Update footnote as “ Note: When there 
are multiple pre -dose assessments, the 
highest non -missing pre -dose 
assessment from day -9 and day 1 is 
identified and captured as "Baseline 
(Derived)" visit ”SAC
2.40. AnalysisEFF_T3 Descriptive Summary of Change from Baseline in Physical 
Activity Measures as Assessed via an Accelerometer.SAC 
2.41. Analysis EFF_T 8 Descriptive Summary of Patient Global Impression of Change SAC 
2.42. Analysis EFF_T 10 Descriptive Summary of Patient Global Rating of Severity. SAC 
2.43. AnalysisEFF_T3 Descriptive Summary of Change from Baseline in FEV1 (L) by 
VisitThis table will include both FEV1 (L )
andPercent Predicted FEV1.SAC
CONFIDENTIA L
200182
682.44. AnalysisEFF_T3 Descriptive Summary of Change from Baseline in Sniff Nasal 
Inspiratory Pressure (SnIP) by VisitSAC 
Exploratory
2.45. AnalysisEFF_T3 Descriptive Summary of Change from Baseline in Handgrip 
strengthFirst left hand, then right hand SAC 
2.46.Analysis EFF_T5Descriptive Summary of Change from Baseline in PROactive 
total and domains scores in different levels of PGICSAC
2.47.AnalysisEFF_T4Analysis of Change from Baseline in Leg Press Strength (kg)by 
Visit excluding the site  (Impact anal ysis) -Repeated 
Measure Mixed ModelFit the model for Table 2.3 by excluding 
the site .SAC
PPD
PPD
CONFIDENTIA L
200182
6912.11.6. Efficacy  Figures
Efficacy: Figures
No.Populati
onIDSL /
Example ShellTitle Programming NotesDeliverable 
[Priority ]
Leg Strength
2.1 AnalysisEFF_F 1Line Plot of Adjusted Mean (9 0% CI) Change from Baseline in 
Leg Press Strength (kg)Over Time –Repeated Measure 
Mixed ModelSeparately for each gender
Use the same footnote about model 
specification as in the corresponding 
analysis tableSAC 
2.2 AnalysisEFF_F1Line Plot of Adjusted Mean (9 0% CI) Percent Change from 
Baseline in Leg Press Strength (%)Over Time –Repeated 
Measure Mixed ModelSeparately for each gender 
Use the same footnote about model 
specification as in the corresponding 
analysis tab leSAC 
Lean Mass
2.3 Analysis EFF_F1Line Plot of Adjusted Mean (9 0% CI) Change from Baseline in 
Appendicular Lean Mass (kg)and Total Lean Mass (kg)as 
Assessed by Dual -energy X -ray Absorptiometry Over Time –
Repeated Measure Mixed ModelSeparately f or each gender by parameter
Use the same footnote about model 
specification as in the corresponding 
analysis tableSAC 
Functional Tests
2.4Analysis EFF_F1Line Plot of Adjusted Mean (9 0% CI) Change from Baseline in 
PROactive Total Score , Difficulty an d Amount Scores Over 
Time -Repeated Measure Mixed ModelSeparately for each gender by parameter
Use the same footnote about model 
specification as in the corresponding 
analysis tableSAC 
2.5Analysis EFF_F1Line Plot of Adjusted Mean (9 0% CI) Change fr om Baseline in 
COPD Assessment Test (CAT) score Over Time -Repeated 
Measure Mixed ModelSeparately for each gender
Use the same footnote about model 
specification as in the corresponding 
analysis tableSAC 
CONFIDENTIA L
200182
702.6Analysis EFF_F1 Line Plot of Adjusted Mea n (90% CI) Change from Baseline in 
total Short Physical Performance Battery (SPPB) score and 
times for chair rise (sec) and 4 m gait speed (sec) –Repeated 
Measure Mixed ModelSeparately for each gender by parameter
Use the same footnote about model 
specif ication as in the corresponding 
analysis tableSAC
Exploratory Variable
2.7Analysis LB9
Box Plot: Change from Baseline in FEV1 (L)Separately for each gender, X -axis is 
visit, Y -axis is change from baseline in 
FEV1 values; SAC 
2.8Analysis LB9BoxPlot: Change from Baseline in Sniff Nasal Inspiratory
Pressure (Snip)Separately for each gender , X-axis is 
visit, Y -axis is change from baseline in 
Snip values;SAC 
2.9Analysis EFF_F1 Descriptive Mean Chan ge from Baseline in Average Daily 
Steps over TimeSAC
12.11.7. Safety Tables
Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Adverse Events (AEs)
3.1.SafetyAE1Summary of All Adverse Events by System Organ Class and 
Preferred TermICH E3Headline 
Results & SAC
3.2.Safety
AE5ASummary of Adverse Events by System Organ Class and 
Preferred Term and Maximum IntensityFor AEs reported more than once by a 
subject, the most severe intensity will 
be included.SAC
CONFIDENTIA L
200182
71Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.3.Safety
AE3 Summary of Common Adverse Events by Ove rall FrequencyICH E3
Note: Common adverse event is 
defined as events occurring more than 
one in either gender.SAC 
3.4.Safety
AE3Summary of Common Severe Adverse Events by Overall 
FrequencyICH E3
Note: Common adverse event is 
defined as events occurring more than 
one in either gender.SAC 
3.5.SafetyAE5ASummary of All Drug -Related Adverse Events by System Organ 
Class and Preferred Term .ICH E3 SAC 
3.6.Safety
AE15Summary of Common Non-serious Adverse Events by System 
Organ Class and Preferred Term (Number of Subjects and 
Occurrences)FDAAA, EudraCT
Note: Common adverse event is 
defined as events occurring more than 
one in either gender.SAC 
3.7.Safety
AE3Summary of Common Drug -Related Severe Adverse Events by 
Overall FrequencyICH E3
Note: Common adverse e vent is 
defined as events occurring more than 
one in either gender.SAC 
Serious and Other Significant Adverse Events
3.8. Safety AE3 Summary of Fatal Serious Adverse Events SAC 
3.9. Safety AE3 Summary of Drug -Related Fatal Serious Adverse Events SAC 
3.10. Safety AE3 Summary of Serious Adverse Events by System Organ Class SAC 
3.11.Safety
AE1Summary of Drug -Related Serious Adverse Events by System 
Organ ClassFDAAA, EudraCTSAC 
CONFIDENTIA L
200182
72Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.12. Safety AE16Summary of Serious Adverse Events by System Organ Class 
and Preferred Term (Number of Participants and Occurrences)FDAAA, EudraCT
3.13. SafetyAE1Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment or Withdrawal from Study by 
System Organ Class and Preferred Term IDSL SAC
Special Interest AEs
3.14.Safety
AE3 Summary of Adverse Events of Special InterestIDSL –To display by page for CV 
events and Liver eventsHeadline 
Results & SAC
Laboratory: Chemistry 
3.15. Safety LB1 Summary of Chemistry Changes from Baseline by Visit ICH E3 SAC 
3.16.Safety LB16 Summary of Chemistry Results by Maximum Grade Increases 
Post-baseline Relative to BaselineICH E3SAC 
3.17.SafetyLB4Summary of Chemistry Shifts from Baseline Relative to Normal 
RangeIDSLSAC
Laboratory: Haematology
3.18. Safety LB1 Summary of Haematology Chan ges from Baseline ICH E3 SAC 
3.19.Safety LB16 Summary of Haematology Results by Maximum Grade 
Increases Post -baseline Relative to BaselineICH E3SAC 
3.20.SafetyLB4Summary of Haematology Shifts from Baseline Relative to 
Normal RangeIDSLSAC
Laboratory: Ur inalysis
3.21. Safety LB1 Summary of Urine Concentration Changes from Baseline ICH E3 SAC 
CONFIDENTIA L
200182
73Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.22.SafetyUR1Summary of Worst Case Urinalysis Results (Discrete or 
Character Values) Post -Baseline Relative to BaselineICH E3 Including g lucose, protein, 
bloodSAC 
3.23.SafetyLB4Summary of Urinalysis Shifts from Baseline Relative to Normal 
RangeIDSLSAC
Laboratory: Hepatobiliary (Liver)
3.24. Safety LIVER10 Summary of Hepatobiliary Laboratory Abnormalities IDSL SAC 
Laboratory: Other
3.25. Safety LB1 Summary of Sex/R eproduc tive HormonesSummarize Testosterone, Free 
Testosterone, Sex hormone -binding 
globulin (SHBG), Follicle -stimulating 
hormone (FSH), Luteinizing hormone 
(LH) and Prostate specific antigen 
(PSA).SAC 
3.26. Safety LB1 Summary of Lipid Panel SAC 
3.27. Safety LB1 Summary of hsCRP, Fibrinogen SAC
ECG
3.28. Safety EG1 Summary of ECG Findings IDSL SAC 
3.29.SafetyEG10Summary of Maximum QTc Values Post -Baseline Relative to 
Baseline by CategoryIDSL SAC 
3.30. Safety EG2 Summary of Change from Baseline in ECG Values by Visit IDSL SAC 
3.31.SafetyEG11Summary of Maximum Increase in QTc Values Post -Baseline 
Relative to Baseline by CategoryIDSL SAC 
Vital Signs
CONFIDENTIA L
200182
74Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.32. Safety VS1 Summary of Change from Baseline in Vital Signs ICH E3 SAC 
3.33.Safety
VS7Summary of Worst Case Vital Signs Resu lts Relative to Normal 
Range /Potential Clinical Importance (PCI) Criteria Post-
Baseline Relative to BaselineIDSL SAC 
Biomarkers
3.34.Safety
LB1 Summary of Change from Baseline in Bone BiomarkersSAC 
3.35.Safety
LB1Summary of Change from Baseline in Reprod uctive Tissue 
BiomarkersSAC 
COPD Events
3.36.SafetySAFE_T1 Summary of COPD EventsSAC
CONFIDENTIA L
200182
7512.11.8. Safety  Figures
Safety : Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Laboratory
3.1. Safety LIVER14 Scatter Plot of Maxi mum vs. Baseline for ALTIDSL SAC 
3.2. Safety LIVER9 Scatter Plot of Maximum ALT vs. Maximum Total BilirubinIDSL SAC 
3.3. Safety EFF_F1Line Plot of Change from Baseline in Sex/reproductive 
Hormones Over Time Each hormone per page SAC 
3.4. Safety EFF_F1Line Plot of Change from Baseline in Metabolic factors Over 
TimeEach factor per pageSAC 
12.11.9. Pharmacokinetics Tables
Pharmacokinetics : Table
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
4.1 PK PK01 Summary of Plasma Concentration Time data     SAC
CONFIDENTIA L
200182
7612.11.10. ICH Listings
ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Subject Disposition
1. Screened ES7 Listing of Reasons for Screen Failure Journal Guidelines SAC 
2.All 
ParticipantsES2 Listing of Reasons for Study Withdrawal           ICH E3 SAC 
3.All 
ParticipantsSD2 Listing of Reasons for Study Treatment Discontinuation   ICH E3 SAC 
4.All 
ParticipantsBL1 Listing of Participants for Whom the Treatment Blind was Bro ken ICH E3 SAC 
5. Enrolled TA1 / CP_RD1x Listing of Planned and Actual Treatments IDSL SAC
Protocol Deviations
6.All 
ParticipantsDV2 Listing of Important Protocol Deviations ICH E3SAC 
7.All 
ParticipantsIE3 Listing of Participants with Inclusion/Exc lusion Criteria 
DeviationsICH E3SAC 
8.All 
ParticipantsPOP_L4 Listing of Protocol Deviations leading to Exclusion from the Per -
Protocol PopulationSAC 
Populations Analysed
9.All 
ParticipantsSP3 Listing of Participants Excluded from Any Population ICH E3 SAC
Demographic and Baseline Characteristics
CONFIDENTIA L
200182
77ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
10.All 
Participants DM2 Listing of Demographic CharacteristicsICH E3
Footnote: Age is imputed when full date 
of birth is not provided.SAC 
11.All 
ParticipantsDM9 Listing of Race ICH E3SAC
Prior and Co ncomitant Medications
12.All 
ParticipantsCP_CM3 Listing of Concomitant MedicationsIDSL
Note: On -Treatment phase includes 
both On -Treatment and Post -Treatment 
concomitant medications.SAC
Exposure and Treatment Compliance
13.All 
ParticipantsEX3 Listing of Investigational Product Exposure Data ICH E3 SAC 
Adverse Events
14. Safety AE8CPa Listing of All Adverse Events ICH E3 SAC 
15. Safety AE8 Listing of Drug -Related Adverse Events SAC 
16. Safety AE7 Listing of Subject Numbers for Individual Adverse Events ICH E3 SAC 
Serious and Other Significant Adverse Events
17. SafetyAE8CPa Listing of Fatal Serious Adverse Events ICH E3SAC 
18. Safety AE8 Listing of Drug -Related Fatal Serious Adverse Events SAC 
19. Safety AE8 Listing of Non -Fatal Serious Adverse Event s ICH E3 SAC 
20. Safety AE14 Listing of Reasons for Considering as a Serious Adverse Event ICH E3 SAC 
CONFIDENTIA L
200182
78ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
21.SafetyAE8 Listing of Adverse Events Leading to Withdrawal from Study / 
Permanent Discontinuation of Study TreatmentICH E3SAC 
Hepatobiliary (Liver)
22.All 
ParticipantsMH2Listing of Medical Conditions for Participants with Liver Stopping 
EventsIDSL SAC
23.All 
ParticipantsSU2Listing of Substance Use for Participants with Liver Stopping 
EventsIDSL only subjects have such eventsSAC 
24.All 
Participan tsLIVER 5 Listing of Liver Monitoring/Stopping Event Reporting IDSL only subjects have such eventsSAC 
All Laboratory
25. Safety LB5A Listing of Clinical Chemistry Laboratory Data ICH E3 SAC 
26. Safety LB5A Listing of Haematology Laboratory Data ICH E3 SAC 
27.SafetyLB14Listing of Clinical Chemistry Laboratory Data with Character 
ResultsIDSL SAC 
28. Safety LB14 Listing of Clinical Haematology Data with Character Results IDSL SAC 
29. Safety LB5A Listing of All Urin e Analysis Data ICH E3 SAC
ECG
30.SafetyEG3 Listing of All ECG Values for Subjects with Any Value of 
Potential Clinical ImportanceIDSLSAC 
31.SafetyEG5 Listing of All ECG Findings for Subjects with an Abnormal ECG 
FindingsIDSLSAC 
32. Safety EG3 Listing of ECG Values of Potential Clinical I mportance IDSL SAC 
CONFIDENTIA L
200182
79ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Vital Signs
33.SafetyVS4Listing of All Vital Signs for Subjects with Any Value of Potential 
Clinical ImportanceIDSLSAC 
34. Safety VS4 Listing of Vital Signs of Potential Clinical Importance IDSL SAC
CONFIDENTIA L
200182
8012.11.11. Non-ICH Listings
Non-ICH: List ings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Study Population
35. Enrolled POP_L1 Listing of Subject Recruitment by Country and Site Number SAC 
36. Screened ES9 Listing of Subject Who were Rescreened SAC 
37.All 
ParticipantsPOP_L2 Listing of Visit DatesSAC 
38. Screened POP_L3 Listing of Study Population SAC 
39.All 
ParticipantsPOP_L5Listing of Disease Stage and Exacerbation HistorySAC 
40.All 
ParticipantsMH2 Listing of Current and Past Medical Conditions at Baseline SAC
41.All 
ParticipantsPOP_L6Listing of Alcohol History and Tobacco Use/Smoking HistorySAC 
42.All 
ParticipantsPOP_L7Listing of Smoking Status Change during the StudySAC
43.All 
ParticipantsPOP_L8Listing of HIV and Hepatitis Test Results SAC 
44. Safety POP_L9 Listing of Investigational Product Accountability SAC 
CONFIDENTIA L
200182
81Safety
45. Safety SAFE_L1 Listing of COPD Exacerbation Log SAC 
46. SafetySAFE_L2 Listing of Hepatic, Prostate and Cardiac Structure assessed via 
MRISAC
47. Safety SAFE_L3 Listing of Change from baseline of Lipids and Sex hormonesListthe sex hormones Testosterone, 
Free Testosterone, Sex hormone -
binding globulin (SHBG), Follicle -
stimulating hormone (FSH), Luteinizing 
hormone (LH) and Prostate specific 
antigen (PSA).SAC
Primar y Efficacy
48. Analysis EFF_L1 Listing of leg Press Strength (kg)Results SAC 
Secondary Efficacy
49. AnalysisEFF_L2 Listing of Appendicular (kg), and Total Lean Mass (kg)as 
Assessed by Dual -energy X -ray Absorptiometry (DXA)SAC 
50. AnalysisEFF_L3Listing of PROactive Endpoints Total score, difficulty and amount 
scores will be displayedSAC 
51. AnalysisEFF_L4 Listing of Total Short Physical Performance Battery (SPPB) 
Score and Times for Chair Rise (sec) and 4 m Gait Speed (sec) 
ResultsSAC 
52. AnalysisEFF_L5 Listing of Constant Work Rate (CWR) Duration (sec) from 
Endurance Shuttle Walking TestSAC 
53. AnalysisEFF_L6 Listing of Peak Performance from Incremental Shuttle Walking 
TestSAC 
54. Analysis EFF_L7 Listing of COPD Assessment Test (CAT) SAC 
55. Analysis EFF_L8 Listing of Patient Global Impression of Change SAC 
56. Analysis EFF_L9 Listing of Patient Global Rating of Severity SAC 
CONFIDENTIA L
200182
8257. AnalysisEFF_L10
Listing of St George Respiratory Questionnaire (SGRQ) ResultsTotal score, impact, symptoms and 
activit y domain scores derived by 
SGRQ -c raw scoresSAC 
58. Analysis EFF_L11 Listing of Spirometry Results SAC 
59. Analysis EFF_L12 Listing of Sniff Nasal Inspiratory P ressure (SnIP) SAC 
60. AnalysisEFF_L13 Listing of Physical Activity Meas ures Assessed via an 
Accelerometer.SAC
Exploratory
61. Analysis EFF_L1 4 Listing of Handgrip strength SAC 
Pharmacokinetics
62. PK PK07 Listing of Plasma Pharmacokinetic Concentration time data SAC
Supportive SAS Listing
63. AnalysisSupportive SAS Listing for the Analysis of Percent Change from 
Baseline in Leg Press Strength (%)by Visit -Repeated Measure 
Mixed ModelSAC
64. Per ProtocolSupportive SAS Listing for Analysis of Percent Change from 
Baseline in Leg Press Strength (%) by Visit -Repeated Measure 
Mixed ModelSAC 
65. AnalysisSupportive SAS Listing for Analysis of Change from Baseline in 
Leg Press Strength (kg) by Visit -Repeated Measure Mixed 
ModelSAC 
66. Per ProtocolSupportive SAS Listing for Analysis of Change from Baseline in 
Leg Press Strength (kg)by Visit -Repeated Measure Mixed 
ModelSAC 
67. AnalysisSupportive SAS Listing for Bayesian Analysis of Percentage 
Change from Baseline in Leg Press Strength (%) by VisitSAC 
CONFIDENTIA L
200182
8368. AnalysisSupportive SAS Listing for Analysis of Percent Change from 
Baseline in Leg Press Strength (%)by Visit -Repeated Measure 
Mixed Model with Exploratory CovariatesSAC
69. AnalysisSupportive SAS Listing for Analysis of Change from Baseline in 
Appendicular (kg), and Total Lean Mass (kg)as Assessed by 
Dual-energy X -ray Absorptiomet ry by Visit -Repeated Measure 
Mixed ModelSAC
70. AnalysisSupportive SAS Listing for Analysis of Percent Change from 
Baseline in Appendicular (%), and Total Lean Mass (%)as 
Assessed by Dual -energy X -ray Absorptiometry by Visit -
Repeated Measure Mixed M odelSAC
71.Analysis Supportive SAS Listing for Analysis of Change from Baseline in 
PROactive Total Score , Difficulty and Amount Scores by Visit -
Repeated Measure Mixed ModelSAC
72.Per Protocol Supportive SAS Listing for Analysis of Change from Baseline in 
PROactive Total Score , Difficulty and Amount Scores by Visit -
Repeated Measure Mixed ModelSAC
73.Analysis Supportive SAS Listing for Bayesian Analysis of Change from 
Baseline in PROactive Total Score , Difficulty and Amount Score
by VisitSAC
74.Analy sis Supportive SAS Listing for Analysis of Change from Baseline in 
COPD Assessment Test (CAT) score byVisit-Repeated 
Measure Mixed ModelSAC
75.Analysis Supportive SAS Listing for Responder Analysis of COPD 
Assessment Test (CAT) SAC
76.Analysis Supp ortive SAS Listing for Analysis of Change from Baseline in 
St George Respiratory Questionnaire (SGRQ) Total Score and 
Domains Score at Day 90 -ANCOVASAC
CONFIDENTIA L
200182
8477.Per Protocol Supportive SAS Listing for Analysis of Change from Baseline in 
St George Respiratory Questionnaire (SGRQ) Total Score and 
Domains Score at Day 90 –ANCOVASAC
78.Analysis Supportive SAS Listing for Responder Analysis of St George 
Respiratory Questionnaire (SGRQ) SAC
79.Analysis Supportive SAS Listing for Bayesian Analysis of Change fro m 
Baseline in St George Respiratory Questionnaire (SGRQ) Total 
Score at Day 90SAC
80. AnalysisSupportive SAS Listing for Analysis of Change from baseline in 
total Short Physical Performance Battery (SPPB) score and 
times for chair rise (sec) and 4 m gait speed (sec) by Visit -
Repeated Measure Mixed ModelSAC
81. Per ProtocolSupportive SAS Listing for Analysis of Change from baseline in 
total Short Physical Performance Battery (SPPB) score and 
times for chair rise (sec) and 4 m gait speed (sec) by Visit -
Repeated Measure Mixed ModelSAC
82. AnalysisSupportive SAS Listing for Bayesian Analysis of Change from 
Baseline in Times for chair rise (sec) by VisitSAC
83.Analysis Supportive SAS Listing for Analysis of Change from Baseline in 
Constant Work Rate ( CWR) Duration (sec) from Endurance 
Shuttle Walking Test at Day 90 –ANCOVA modelSAC
84.Per Protocol Supportive SAS Listing for Analysis of Change from Baseline in 
Constant Work Rate (CWR) Duration (sec) from Endurance 
Shuttle Walking Test at Day 90 –ANC OVA modelSAC
85.Analysis Supportive SAS Listing for Analysis of Percent Change from 
Baseline in Constant Work Rate (CWR) Duration (%)from 
Endurance Shuttle Walking Test at Day 90 –ANCOVA modelSAC
CONFIDENTIA L
200182
8586.Analysis Supportive SAS Listing for Bayesian Analysis of Change from 
Baseline in Constant Work Rate (CWR) Duration (sec) from 
Endurance Shuttle Walking Test at Day 90SAC
87.Analysis Supportive SAS Listing for Analysis of Change from Baseline in 
Peak Performance from Incremental Shuttle Walking Test at 
Day 90 – ANCOVASAC
88.Analysis Supportive SAS Listing for Analysis of Percent Change from 
Baseline in Peak Performance from Incremental Shuttle Walking 
Test (%)at Day 90 -ANCOVASAC
89.Analysis Supportive SAS Listing for Analysis of Change from Baselin e in 
Leg Press Strength (kg) by Visit excluding the site  
(Impact analysis) -Repeated Measure Mixed ModelSAC
PPD
CONFIDENTIA L
200182
8612.12. Appendix 12: Example Mock Shells for Data Display s
STUDY POPULATION 
Listings 
Example : POP_L1
Protocol: xxxxxxx                                                                               Page 1 of 1
Population: Screened
Listing xx
Listing of Subjects Recruitment by Country and Site Number
  Sex: Female
Country Site Id./
Investigator NameUnique Subject Id Randomization 
NumberAssigned Treatment Treatment 
Start Date
xxx xx xxx DDMMMYXXX
xxx xx DDMMMYXXX
Programming note: continue with Sex= Male
CONFIDENTIA L
200182
87Example : POP_L2
Protocol: XXXXXXX                                                                             Page 1 of x
Population: All Participants
Listing xx
Listing of Visit Dates
Country: xxxxx
Centre ID: xxxxxx
Investigator: AAAAAA
SexUnique
Subject 
Id.Treatment Nominal CRF 
VisitVisit Start 
DateVisit End Date Analysis Vis it 
[1]Study Day
FxxxxxGSK2881078 Screening DDMMMYYYY DDMMMYYYY Screening -18
Day 1/Visit 3 DDMMMYYYY DDMMMYYYY Day 1   1
Visit 4 DDMMMYYYY DDMMMYYYY Visit 4 xx
Visit 5 DDMMMYYYY DDMMMYYYY Visit 5 xx
Unscheduled DDMMMYYYY DDMMMYYYY Visit 6 xx
DDMMMYYYY DDMMMYYYY Visit 7 xx
...
xxxxxPlacebo Screening DDMMMYYYY DDMMMYYYY Screening -29
Day 1 DDMMMYYYY DDMMMYYYY Day 1 -1
...
[1] Analysis Visit is the slotted visits and it is der ived by applying the slotting algorithm to Visit Start Date.
Programmer’s note: repeat for each site within country, then repeat for each country.
CONFIDENTIA L
200182
88Example : POP_L3
Protocol: XXXXXXX                                                                             Page 1 of x
Population: Screened
Listing xx
Listing of Study Populations
Sex: Female
Treatment: None
Site 
Id./Investi
gator 
Id./Investi
gator NameRandomized All 
ParticipantsAnalysis Per-
Protocol Safety
xxxxx/xxx No No No No No
xxxxx/xxx No No No No No
xxxxx/xxx No No No No No
...
Sex: Female
Treatment: GSK2881078
Site 
Id./Investi
gator 
Id./Investi
gator NameRandomized All 
Participants Analysis Per-
Protocol Safety
xxxxx/xxx Yes Yes Yes Yes Yes
xxxxx/xxx Yes Yes Yes No No
xxxxx/xxx Yes No No No No
...
CONFIDENTIA L
200182
89Treatment: Placebo
...
Programmer’s note: Include all analysis populations specified in RAP and give its definition as a footnote.
Example : POP_L4
Protocol: xxxxxxx                                                                               Page 1 of 1
Population: All Participants
Listing xx
Listing of Protocol Deviations Leading to Exclusion from the Per -Protocol Population
Sex: Female
Treatment: GSK2881078
Inv. Unique
Subj.AgeProtocol Deviations Deviatio n Start 
Date/ 
Day
xxxxx xxx xxxxxxxxxxxxxxxxxxxxxx DDMMMYXXX/
XXX
xxx xxxxxxxxxxxxxxxxxxxxxx DDMMMYXXX/
XXX
...
...
CONFIDENTIA L
200182
90Example : POP_L5
Protocol: XXXXXXX                                                                             Page 1 of x
Population: All Participants
Listing xx
Listing of Disease Stage and Exacerbation History
Sex: Female
Treatment: GSK2881078
Site Id./            
Unique 
Subject 
Id.Disease 
Initial 
Diag. DateAge
(yrs)Exacerbation History
(Number of Exacerbations in the last 12 Months)
Without 
Corticosteroids 
and/or 
AntibioticsNeed 
Corticosteroids 
and/or 
AntibioticsRequired 
Hospitalised Period Prior to 
Visit [1]
xxx/xxx DDMMMYYYY xx xx xx xxxx xx
xxx/xxx DDMMMYYYY xx
xxx DDMMMYYYY xx
xxx DDMMMYYYY xx
xxx DDMMMYYYY xx
[1] Period Prior to Visit is the Evaluation Interval considered while collecting Exacerbation history.
CONFIDENTIA L
200182
91Example : POP_L6
Protocol: XXXXXXX                                                                             Page 1 of x
Population: All Participants
Listing xx
Listing of Alcohol and Tobacco Use/Smoking History
Sex: Female
Treatment: GSK2881078
Site 
Id./Uniq
ue 
Subject 
IdAlcohol Tobacco Use and Smoking History
Assessment 
DateAlcohol 
History/# 
Unit Per 
WeekTobacco 
Smoking 
HistoryLast Smoke 
DateSmokeless
Tobacco
Use HistoryNumber of 
Cigarettes 
per DayYears 
Smoking 
TobaccoPack 
Year
xxx/xxx DDMMMYYYY xx/xx Smoked DDMMMYYYY Current 
Userxxxx xx
xxx/xxx DDMMMYYYY xx
CONFIDENTIA L
200182
92Example : POP_L8
Protocol: XXXXXXX                                                                             Page 1 of x
Population: All Participants
Listing xx
Listing of HIV and Hepatitis Test Results
Sex: Female
Treatment: GSK2881078
Site 
Id./Uniqu
e Subject 
Id.Sample Date Age
(yrs)HIV Test 
Results/[1]Hepatitis B Test 
ResultHepatitis C Test 
Result/RBA PCR [2]
xxx/ DDMMMYYYY xx Negative Non-Reactive Non-Reactive
xxx DDMMMYYYYxx Non-Reactive Reactive
xxx/ DDMMMYYYY xx Non-Reactive Non-Reactive
xxx DDMMMYYYY xx Non-Reactive Non-Reactive
xxx DDMMMYYYY xx Non-Reactive Non-Reactive
    [1] only when HIV test is reactive;
    [2] only when Hepatitis C test is reactive
CONFIDENTIA L
200182
93Example : POP_L9
Protocol: XXXXXXX                                                                             Page 1 of x
Population: Safety
Listing xx
Listing of Investigational Product Accountability
Sex: Female
Treatment: GSK2881078
Site 
Id.Unique 
Subject 
Id.Compliance
PercentageDate IP
Dispensed/
Study DayDate IP
Returned
/
Study 
DayTablets
DispensedTablets
ReturnedAmoun
t
TakenNumber 
of 
Tables 
Lost Container
Number
xxxxx xxxx xx DDMMMYYYY/
xxDDMMMYYY
Y/
xxxx xx xxxx xxxxxx
xx xx xxxx xxxxxx
xx DDMMMYYYY/
xxDDMMMYYY
Y/
xxxx xx xxxx xxxxxx
xx xx xxxx Xxxxxx
Note :Treatment compliance = 100 * (Total Amount Taken/ ( Actual t reatment duration in days* frequency)).
CONFIDENTIA L
200182
94EFFICACY
Tables 
Example : EFF_T1
Protocol: XXXXXXX                                                                              Page 1 of 1
Population: XXXXXXX
                                                 Table xx
               xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
             
  Sex: Female                                                  
                                                                                             
                                                               Placebo                      GSK2881078
  Visit                                                       (N=xxx)                     (N=xxx)
  -------------------------------------------------------------------------------------- ------------------
  Visit X,  n                                                 xxx                         xxx
  Day X     Adjusted Mean [1] (SE)                           x.xxx (x.xxx)               x.xxx (x.xxx )
            90% C.I.                                       (x.xxx, x.xxx)              (x.xxx, x.xxx)
  
            GSK2881078 vs. Placebo
            Difference [2]                                                               x.xxx
            90% C.I.                                                                   (x.xxx, x.xxx)       
            p-value                                                                       xxx
[1] Estimates were calculated from a repeated measures model including the following covariates: Treatment, Day, 
Treatment* Day and baseline xxxxxx, with Day as the repeated factor. In case of violation of the assumptions, the 
same model is fitted with log of ratio to baseline and replacing the covariate baseline xxxxx with log baseline 
xxxxx. The correlation matrix for within -subject errors used is unstructured.
[2] GSK2881078 -Placebo.
CONFIDENTIA L
200182
95Programming note: Please repeat for Sex: Male.
Programming note: Update the footnotes with the appropriate endpoints and covariate as per RAP.
If data has been log -transformed , thenuse the following shell:
Protocol: XXXXXXX                                                                              Page 1 of 1
Population: XXXXXX 
                                                 Table EFF_T1
                  xxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
  Sex: Female                                                  
                                                                                                 
                                                             Placebo                      GSK2881078
  Visit                                                     (N=xxx)                     (N=xxx)
  ----------------------------------------------------------------------------------------------- ---------
  Visit X,   n                                                xxx                         xxx
  Day X      Model-Adjusted Geometric Mean for             xx.xx (x.xxx, x.xxx)        xx.xx (x.xxx, x.xxx)     
             Ratio to Baseline (90% CI)[1]                                  
  
             Adjusted Treatment Ratio of                                         xx.xx (x.xxx, x.xxx)
             Geometric Means(90% CI)[2]                                                       
             p-value                                                                        xxxx
             
[1] Estimates were calculated from a repeated measures model including the following covariates: Treatment, Day, 
Treatment* Day and baseline xxxxxx, with Day as the repeated factor. In case of violation of the assumptions, the 
CONFIDENTIA L
200182
96same model is fitted with log of ratio to baseline and replacing the covariate baseline xxxxx with log baseline 
xxxxx. The correlation matrix for within -subject errors used is unstructured.
[2] GSK2881078 ratio to Placebo.
Programming note: Please repeat for Sex: Male.
Programming note: Update the footnotes with the appropriate endpoints and covariate as per RAP.
Example : EFF_T2
Protocol: XXXXXXX                                                                              Page 1 of 1
Population: XXXXXXX
                                                 Table xx
               xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
             
  Sex: Female                                                  
  
                                                              Placebo                      GSK2881078
  Visit                                                      (N=xxx)                     (N=xxx)
  --------------------------------------------------------------------------------------------------------
  Visit X,  n                                                 xxx                         xxx
  Day X     Posterior Adjusted Mean (SD)[1]                   x.xxx (x.xxx)                x.xxx (x.xxx )
            90% HPD Credible Interval                          (x.xxx, x.xxx)              (x.xxx, x.xxx)
  
            GSK2881078 vs. Placebo
            Posterior adjusted mean for                                                    x.xxx
            treatment difference [SD][2]
            90% HPD Credible Interval                                                   (x.xxx, x.xxx)   
            Posterior probability treatment                                                x.xxx
            difference >=x% 
            Posterior probability treatment                                                x.xxx
            difference >x% 
            Posterior probability treatment                                                x.xxx
            difference <x%                                                              
                                                             
CONFIDENTIA L
200182
97                                                            
[1] Estimates were calculated fro m a Bayesian repeated measures model including the following covariates: Treatment,
Day, Treatment* Day and baseline xxxxxx, with Day as the repeated factor. 
[2] GSK2881078 -Placebo.
Note: HPD -Highest Posterior Density.
Programming note: Please repeat fo r Sex: Male.
Programming note: Update the footnotes with the appropriate endpoints and covariate as per RAP. Add the 
probabilities x% based on the domain.
Example : EFF_T3
Protocol: XXXX                                                                                Page 1 of 1
Population: XXXXXX
                                                 Table XX
                     xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
                                        
Parameter: xxxxxxxxxxxxxxxxxxx
                                                        Female                          Male
                                            ------------------------------ ------------------------------
                                                                            
                                            Placebo        GSK2881078              Placebo        GSK2881078
  Visit                         Statistics (N=20)        (N=22)           (N=24)        (N=22)
  ------------------------------ -------------------------------------------------------------------------
  Baseline                       n           xx           xx               xx             xx
                                 Mean       xxx.x         xxx.x            xxx.x         xxx.x
                                 SD          xx.xx         xx.xx            xx.xx          xx.xx
                                 Median      xx.x         xxx.x            xxx.x          xxx.x
                                 Min.        xx            xx               xx            xxx
                                 Max.       xxx           xxx              xxx            xxx
  Visit X, Day X                 n           xx           xx               xx             xx
                                 Mean       xxx.x         xxx.x            xxx.x          xxx.x
                                 SD          xx.xx         xx.xx            xx.xx          xx.xx
                                 Median      xx.x         xxx.x            xxx.x          xx x.x
                                 Min.        xx            xx               xx            xxx
                                 Max.       xxx           xxx              xxx            xxx
CONFIDENTIA L
200182
98  Change from Baseline at Visit  n           xx           xx               xx             xx
  X, Day X                       Mean       xxx.x         xxx.x            xxx.x          xxx.x
                                 SD          xx.xx         xx.xx            xx.xx          xx.xx
                                 Median      xx.x         xxx.x            xxx.x          xxx.x
                                 Min.        xx            xx               xx            xxx
                                 Max.       xxx           xxx              xxx            xxx
(a)Note: When there are multiple pre -dose assessments, the latest non -missing pre -dose assessment is identified and 
captured as "Baseline (Derived)" visit.
(b)Note: "Visit X, Day X" is considered as Baseline.
Programming note: Repeat for other visits and summa rize its change from baseline, percent change from baseline and 
ratio to baseline whereever applicable Programming note: If the baseline is a derived visit add the footnote (a) 
else if it is a single visit add footnote (b)
Example : EFF_T4
Protocol: XXXXXX X                                                                              Page 1 of 1
Population: XXXXXXX
Table xx
Analysis of Changefrom Baseline in Leg Press Strength (kg) by Visit excluding the site  (Impact analysis) -
Repeated Measure Mi xed Model
             
  Sex: Female                                                  
                                                                                             
                                                               Placebo                      GSK2881078
  Visit                                                       (N=xxx)                     (N=xxx)
  --------------------------------------------------------------------------------------------------------
  Visit X,  n                                                 xxx                         xxx
  Day X     n1                                                 xxx                         xxx
            Adjusted Mean [1] (SE)                           x.xxx (x.xxx)               x.xxx (x.xxx )
            90% C.I.                                       (x.xxx, x.xxx)              (x.xxx, x.xxx)
  
            GSK2881078 vs. Placebo
            Difference [2]                                                               x.xxx
            90% C.I.                                                                   (x.xxx, x.xxx)       
            p-value                                                                         xxx
PPD
CONFIDENTIA L
200182
99[1] Estimates were calculated from a repeated measures model including the following covariates: Treatment, Day, 
Treatment* Day and baseline leg strength with Day as the repeated factor. In case of violation of the assumptions, 
the same model is fitted with log of ratio to baseline and replacing the covariate ba seline leg strength with log 
baseline leg strength. The correlation matrix for within -subject errors used is unstructured.
[2] GSK2881078 -Placebo.
Note: n1 indicates the number of analysable subjects excluding the site .
Programming note: Please repeat for Sex: Male.
Programming note: Update the footnotes with the appropriate endpoints and covariate as per RAP.
PPD
CONFIDENTIA L
200182
100Example : EFF_T5
Protocol: xxxxxxx                                                                              Page 1 of 1
Population: Ana lysis 
Table XX
Analysis of Change from Baseline in PROactive total and domains scores in different levels of PGIC
Parameter: XXXXXXXXXXX
Visit PGIC Level Statistics Males
(N=XXX)Females
(N=XXX)Overall 
(Males + Females)
(N=XXX)
Visit X, Much Better n xx xx Xx
Day X Mean xx.xx xx.xx xx.xx
SD xx.xxx xx.xxx xx.xxx
Median xx.xx xx.xx xx.xx
Min. xx.x, xx.x xx.x, xx.x xx.x, xx.x
Max. xx.x, xx.x xx.x, xx.x xx.x, xx.x
Better n xx xx Xx
Mean xx.xx xx.xx xx.xx
SD xx.xxx xx.xxx xx.xxx
Median xx.xx xx.xx xx.xx
Min. xx.x, xx.x xx.x, xx.x xx.x, xx.x
Max. xx.x, xx.x xx.x, xx.x xx.x, xx.x
CONFIDENTIA L
200182
101Programming Note: Continue with all PGIC Levels and add levels ‘Much Worse a nd Worse’ and ‘Better and Much Better’ 
to the existing levels of PGIC.  Repeat for Day 90 and Parameters of PROactive Scores.
Example : EFF_T6
Protocol: XXXXXXX                                                                              Page 1 of 1
Population: Analysis 
                                                 Table XX
                       xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
Sex: Female
Visit Treatment N Responder Rate
n1/n (%)Odds Ratio (90% 
C.I.)
Visit X, Day 
XGSK288107 8 xx xx/xx (xx.x%) x.xxx (x.xxx, x.xxx)
Placebo xx xx/xx (xx.x%)
Note: A subject is defined as a responder when the total score at a post -baseline visit decreases
XXor more from baseline total score.
Note: n1 is the number of res ponders in each treatment group and the percentages are calculated
using n.
Note: The confidence interval for odds ratio ( GSK2881078 /Placebo) is calculated using the Exact method.
Programming note: continue for the next visit and repeat for Sex: Male.
CONFIDENTIA L
200182
102Example : EFF_T7
Protocol: XXXXXXX                                                                              Page 1 of 1
Population: XXXXXXX
                                                 Table XX
              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
             
  Sex: Female                                                  
                                                                                             
                                                               Placebo                      GSK2881078
  Parameter                                                    (N=xxx)                     (N=xxx)
  --------------------------------------------------------------------------------------------- -----------
  xxxxxxxx  n                                                 xxx                         xxx
            Adjusted Mean [1] (SE)                           x.xxx (x.xxx)               x.xxx (x.xxx )
            90% C.I.                                       (x.xxx, x.xxx)              (x.xxx, x.xxx)
  
            GSK2881078 vs. Placebo
            Difference [2]                                                               x.xxx
            90% C.I.                                                                   (x.xxx, x.xxx)       
[1] Lsmeans of change from baseline for each treatment group as well as the difference of lsmeans of
change from baseline is estimated from ANCOVA model with baseline score as the covariate adjusting
CONFIDENTIA L
200182
103for the treatment. In case of violation of the assumptions, the same model is fitted with log of ratio to 
baseline and replacing the covariate baseline with log baseline. 
[2] GSK2881078 -Placebo.
Example : EFF_T8
Protocol: XXXXXXXX                                                                                  Page 1 of x
Population: Analysis 
Table xx
Descriptive Summary of Patient Global Impression of Change 
Sex: Female
Visit Treatment Nn PGIC Category
Much Worse Worse Slightly 
WorseNo Change Slightly 
BetterBetter Much 
Better
Day 14 GSK2881078 xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
Placebo xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
Day 28 GSK2881078 xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
Placebo xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
…..
Note: The percentages have been calculated based on n.
Programming note: Continue with Visit= Day 56, Day 90 and then repeat for Sex: Male
CONFIDENTIA L
200182
104Example : EFF_T9
Protocol: XXXXXXXX                                                                                  Page 1 of x
Population: Analysis 
Table XX
Descriptive Summary of Patient Global Rating of Severity 
Sex: Female
Treatment: Placebo
Analysis 
VisitNn PGRS Category
None Mild Moderate Severe Very Severe
Baseline xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
Day 90 xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
xxxxxx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%) xx (xx.x%)
…..
Programming note: repeat for Sex: Male
CONFIDENTIA L
200182
105Figures 
Example : EFF_F1
Protocol: XXXXXXX                                                                                  Page 1 of x
Population: XXXXXXXX
Figure xx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
GSK Placebo
CONFIDENTIA L
200182
106Listings
Example : EFF_L1
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing XX
                                        Listing of Leg Press Strength (kg)Results
Sex: Female
Treatment: XXXXX
Site Id/
Unique 
Subject IdVisit / 
Analysis 
VisitAssessment
Date/DayParameter Leg Press 
Performed?
(if no, 
provide 
reason)Assessment
ValueChange/Percent 
Change from 
Baseline
Unscheduled / 
Visit X Day DDMMMYYYY/1 Number of 
Successful 
LiftsYes xx xxxx / xxx.x
No
Starting 
Lift 
Weight 
(Unit)Yes xx (xxx) xxxx / xxx.x
Last 
Successful 
Lift 1-RM 
(Unit)No
Note: Baseline value will be the latest pre -dose assessment with a non -missing value, including those from 
unscheduled visits .
Programming note: Sorted by treatment, Center, Subject, Visit and continue for SEX: Male
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
CONFIDENTIA L
200182
107Example : EFF_L2
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
         Listing of Appendicular (kg), and Total Lean Mass (kg)as Assessed by Dual -energy X -ray Absorptiometry 
(DXA)
Sex: Female
Treatment: XXXXXXXXXXX
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssessment
Date/DayAppendicular Lean Mass Total Lean Mass
Assessment
(Unit)Change from 
Baseline 
(Unit)Assessment 
(Unit)Change from 
Baseline
(Unit)
xxxx/xxxx Day 1 / 
BaselineDDMMMYYYY/1 xx (xxx) xx (xxx)
Unscheduled 
/ Visit X 
Day Xxx (xxx) xx (xxx) xxxx / xxx.x
                      
Note: "Visit 3, Day 1" is considered as Baseline.
Programming note: Sorted by treatment, Center, Subject, Visit a nd continue for SEX: Male
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
CONFIDENTIA L
200182
108Example : EFF_L3
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
                                         Listing of PROactive Endpoints
Sex: Female
Treatment: XXXX
Site Id/
Unique 
Subject IdAnalysis Visit Individual Component Score Total Score
Amount
/Change from 
BaselineDifficulty /Change 
from BaselineAssessment Change from 
Baseline
xxxx/xxxx Baseline xx xx xx 
Visit X Day X xx /xxx xx /xxx xx xxxx
                      
Note: "Visit 3, Day 1" is considered as baseline and is calculated as average of the data collected from the 7 -day 
period after  Day -9 device dispense.
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
CONFIDENTIA L
200182
109Programming note: Sor ted by treatment, Center, Subject,Visit and continue for SEX: Male
Example : EFF_L4
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of Total Short Phy sical Performance Battery (SPPB) Score and Times for Chair Rise (sec)and 4 m Gait Speed 
(Sec) Results
Sex: Female
Treatment: XXXX
Site 
Id/
Unique 
Subjec
t IdVisit / 
Analysis 
VisitSPPB  
Perfo
rmed? Assessment
Date/DayBalance 
TestsGait Speed Tests Chair Stand Test SPPB 
Total 
Score Total 
Balance 
ScoreGait 
Test 
Perfo
rmed?Walking 
AidsTime 
for the 
Fastest 
Walk 
(Unit)4 
Meter 
Walk 
Test 
ScoreFive 
Successful 
Stand Time 
(unit)Repeated 
Chair 
Test 
Score
xxxx/x
xxxBaseline YesDDMMMYYYY/1 xx Yes xxxxxx(xx) xxxx (xxx) xx (xxx) xxxx
No
Unschedu
led / 
Visit X 
Day XYes xxxx
                      
Note: Baseline value will be the latest pre -dose assessment with a non -missing value, including those from 
unscheduled visits.
Programming note: Sorted by treatment, Center, Subject, Visit and continue for SEX: Male
CONFIDENTIA L
200182
110Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L5
Protocol: X XXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of Constant Work Rate (CWR) Duration (sec)from Endurance Shuttle Walking Test
Sex: Female
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssesment 
Date/DayEndurance
Time 
(seconds)Distance 
Walked 
(meters)Reason for 
Stopping 
TestEndurance 
Time Change 
from Baseline 
Day 
1/BaselineDDMMMYYYY xx xx xxxxx
Unscheduled 
/ Visit X 
Day XDDMMMYYYY xx xx xxxxx xxxx
                      
CONFIDENTIA L
200182
111Note: "Visit 3, Day 1" is considered as Baseline.
Programming note: Sorted by treatment, Center, Subject, Visit and continue for SEX: Male
Programming note: Use assessment datetime instead of date if ti me collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L6
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of Peak Performance from Incremental Shuttle Walking Test 
Sex: Female
Treatment: XXXXXX
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssesment 
Date/DayMaximum 
Distance Walked 
(meters)Speed 
(km/hr)Endurance
Walking 
Speed 
LevelReason for 
Stopping 
TestMax Walked 
Distance 
Change from 
Baseline 
Day -9 DDMMMYYYY xxx xx xx xxxxx
Day 1 / 
BaselineReason for 
Stopping 
Test
Unscheduled 
/ Visit X 
Day XDDMMMYYYY
xxxx 
                      
CONFIDENTIA L
200182
112Note: When there are multiple pre -dose assessments, the highest non -missing pre -dose assessment from day -9 and day 
1 is identified and captured as "Baseline (Derived)" visit.
Programming note: Sorted by treatment, Center, Subject, Visit and continue for SEX: Male
Programming note: Use assessment datetime ins tead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L7
Protocol: XXXXXXX Page 1 of 1
Population: Analysis
Listing xx
Listing of COPD Assessment Test (CAT) 
Sex: Female
Treatment: XXXXXX
Individu al Question Score
Total 
Score/Chang 
from BaselineSite 
Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssesment 
Date/Day
1 2 3 4 5 6 7 8
xxxxxx/
xxxxxxXx DDMMMYYYY Xx xx xx xx xx xx xx xx
xxxxxx/
xxxxxx Unscheduled 
/  Day xxDDMMMYYYY
CONFIDENTIA L
200182
113Note: 1="Frequency of Cough", 2="Amount of Phlegm in My Chest", 3="Tightness in Chest",
4="Breathless Walking Upstairs", 5="Limited Doing Home Activities", 6="Confident Leaving Home",
7="Sleeping Soundly", 8="Amount of Energy".
Note: "Visit 3, Day 1" is considered as Baseline.
Programming note: Sorted by treatment, Center, Subjects, Visit and continue for SEX: Male
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L8
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of Patient Global Impression of Change
Sex: Female
Treatment: XXXXXX    
Site 
Id/
Unique 
Subject 
IdAssessment 
Date/DayVisit / 
Analysis 
VisitMuch Worse Worse Slightly 
WorseNo Change Slightly 
BetterBetter Much 
Better
DDMMMYYYY 
/14Visit x 
/ Visit 
X Day XNo No No No Yes No No
DDMMMYYYY/1 xx
                      
Programming note: Sorted by treatment, Center,Subjects, Visit and continue for SEX: MalePGIC Category
CONFIDENTIA L
200182
114Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L9
Protocol: XXXXXXXX                                                                                  Page 1 of x
Population: Analysis 
Listing xx
Listing of Patient Global Rating of Severity (PGRS) 
Sex: Female
Treatmet: XXXXX
Site Id/
Unique 
Subject IdAssessment 
Date/Day Visit / 
Analysis 
VisitPGRS Category
None Mild Moderate Severe Very Severe
Xxxx/xxxx Baseline 
/ Visit 
X Day XYes
…..
CONFIDENTIA L
200182
115Programming note: Sorted by treatment, Center, Subjects, Visit and continue for SEX: Male
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L10
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of St. George Respiratory Questionnaire (SGRQ) Results
Sex: Female
Treamtment: XXXX
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssessment
Date/DayIndividua l Domain Score Total Score
Symptoms
/Change from 
BaselineActivity 
/Change from 
BaselineImpacts/Change 
from BaselineAssessment Change 
from 
Baseline
xxxx/xxxx Baseline 
/ Visit X 
Day XDDMMMYYYY/1 xx xx xx xx xxxx
Unschedu l
ed / 
Visit X DDMMMYYYY/1 xx /xxx xx /xxx xx /xxx xx xxxx
CONFIDENTIA L
200182
116Day X
     
                 
Note: "Visit 3, Day 1" is considered as Baseline.
Programming note: Sorted by treatment, Center, Subjects, Visit and continue for SEX: Male
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L11
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of Spirometry Results
Sex: Female
Treatment: XXXXX
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssesment  
Date/DayFEV1 
(L)Predicted 
FEV1 (L)Percent 
Predicted 
FEV1 (%)FVC 
(L)Predicted 
FVC (L)Percent 
Predicted
FVC (%)FEV1/FVC
xxxx/xxxx Screening/
Baseline DDMMMYYYY:hh:mm/ -
xxxxxx xx xx xxxxx xx xx.x
Day 
1/Visit X 
Day XDDMMMYYYY:hh:mm/1 xxxx xx xx xxxxx xx xxx.x
CONFIDENTIA L
200182
117                      
Note: Baseline value will be the latest pre -dose assessment with a non -missing value, including those from 
unscheduled visits .
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Programming note: Sorted by treatment, Center, Subje cts, Visit and continue for SEX: Male
Example : EFF_L12
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of Sniff Nasal Inspiratory Pressure (SNIP)
Sex: Female
Treatment: XXXX
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssesment 
Datetime/DayMaximum 
SnIPMaximum SnIP 
Change from 
Baseline
xxxx/xxxx Screening/
Baseline  DDMMMYYYY:hh:mm/ -xx xx.x
Unscheduled DDMMMYYY Y:hh:mm/1 xxx.x
CONFIDENTIA L
200182
118/ Visit X 
Day X
                     
                     
Note: Baseline value will be the latest pre -dose assessment with a non -missing value, including those from 
unscheduled visits .
Programming note: Sorted by treatment, Center, Subjects, Visit and continue for SEX: Male
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L13
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
Listing of Handgrip Strength
Sex: Female
Treatment: XXXX
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssessment
Date/DayLeft or 
RightPerformed?
(No,reason) Reading 1 Reading 2Reading 3 Average of 
3 Readings
xxxxxxx Day 
1/BaselineDDMMMYYYY 
/-xxxx xx xx xx xxxxx xx
CONFIDENTIA L
200182
119Unsheduled 
/ Visit X 
Day XDDMMMYYYY 
/1xx xx xx xx xxxxx xx
  
Note: Baseline value will be the latest pre -dose assessment with a non -missing val ue, including those from 
unscheduled visits .
Programming note: Sorted by treatment, Center, Subjects, Visit and continue for SEX: Male
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Example : EFF_L14
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Analysis
Listing xx
                          Listing of Physical Activity Measures Assessed via a n Accelerometer
Sex: Female
Treatment: XXXX
Site Id/
Unique 
Subject IdAnalysis Visit
Weekly average 
stepsWeekly Average 
Wear durationNumber of 
days with 
wear 
duration Weekly 
Average 
Vector 
magnitude Weekly Average 
Moderate/vigorous 
activity duration
CONFIDENTIA L
200182
120more than 
8 hunit/wear 
time
xxxx/xxxx Baseline xx xx Xx xx 
Visit X Day X xx /xxx xx /xxx xx xx xxxx
                      
Note: "Visit 3, Day 1" is considered as baseline and is calculated as average of the data coll ected from the 7 -day 
period after  Day -9 device dispense.
Programming note: Use assessment datetime instead of date if time collected and update the label as “Assessment
Datetime/Day”
Programming note: Sorted by treatment, Center, Subject,Visit and continue for SEX: Male
SAFETY
Tables
Example: SAFE_T1
Protocol: 200182                                                                                 Page 1 of 1
Population: Safety
CONFIDENTIA L
200182
121                                                 Table xx
                                           Summary of COPD Events
                                                  Female                             Male
                                     --------------------------------   --------------------------------
                                                    
                                     Placebo         GSK2881078         Total     Placebo        GSK2881078         
Total
                                     (N=xx)         (N=xx)               (N=xx)         (N= xx)     
    ---------------------------------------------------------------------------------------------------
    Number of events in total          x (x%)        x (x%)       x       x (x%)            x (x%)     x   
         Number of exacerbating pa tients        x (x%)        x (x%)       x       x (x%)            x (x%)     x   
CONFIDENTIA L
200182
122Listings 
Example: SAFE_L1
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Safety
Listing xx
Listing of COPD Exacerbation Log
Sex: Female
Treatment: XXXX
Site 
Id./       
Unique 
Subject 
Id.Onset 
Date/Day/
Resolution
DateOutcome Primary 
Cause 
(Other, 
Specify)12345 6 78
DDMMMYYYY 
/xx/DDMMYYYYxx Other, xxx NoNoNoNoNo No Noxxxx
DDMMMYYYY/1 xx xx Yes, 
xxxx
                      
Note: 1= withdrawn due to the exacerbation, 2=corticosteroids taken for this exacerbation, 3=antibiotics taken for 
this exacerbation, 4= hospitalized due to this exacerba tion, 5=visited the emergency room, 6=intubated for this 
exacerbation, 7=medication taken for this exacerbation, 8=adverse event reference identifier
Programming note: If medications is taken, show the reference identifier; Sorted by treatment, Center, S ubjects and 
continue for SEX: Male
CONFIDENTIA L
200182
123Example: SAFE_L2
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Safety
Listing xx
                     Listing of Hepatic, Prostate and Cardiac S tructure assessed via MRI
Sex: Female 
Treatment: XXXX
Site Id/
Unique 
Subject 
IdVisit / 
Analysis 
VisitAssessment
Date/DayLiver 
Volume 
(Unit)Spleen 
Volume 
(Unit)Prostate 
Volume 
(Unit)Left 
Ventricular
Volume 
(Unit) Left 
Ventricular
Ejection
FractionLeft 
Ventricular 
End 
Diastolic 
Volume 
Index/ Left 
Ventricular 
End 
Systolic 
Volume 
Index
xxxx/xxxx Day 
1/BaselineDDMMMYYYY 
/1xx xx xxxxx xx xx.x xx
Unsheduled 
/ Visit X 
Day XDDMMMYYYY 
/xxxx xx xxxxx xx xxx.x xx
                      
Note: "Visit 3, Day 1"  is considered as Baseline.
Programming note: Sorted by treatment, Center, Subjects, Visit and continue for SEX: Male
CONFIDENTIA L
200182
124Example : SAFE_L3
Protocol: XXXXXX                                                                                  Page 1 of x
Population: Safety
Listing xx
                     Listing of Change from baseline of Lipids and Sex hormones
Sex: Female
Treatment: XXXX
Site Id/
Unique 
Subject 
IdTest 
(Units)Visit / 
Analysis 
VisitAssesment 
Datetime/DayAnalysis 
ValueChange from 
Baseline
xxxx/xxxx PSA Screening/
Baseline  DDMMMYYYY:hh:mm/ -xx xx.x
Unscheduled 
/ Visit X 
Day XDDMMMYYYY:hh:mm/1 xxx.x xxxx
                     
Note: The baseline value will be the latest pre -dose assessment between Screening and Day 1 with a non -missing 
value, including those from unscheduled visits.